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I 
Zusammenfassung 
Die Fortschritte in der Gentherapie bergen große Hoffnungen für viele Patienten mit 
seltenen genetischen Krankheiten, Krebsleiden und Herz-Kreislauf-Erkrankungen. Die 
Sicherheit der gentherapeutischen Ansätze bereitet jedoch weiterhin Schwierigkeiten, was eine 
schnelle Entwicklung und klinische Anwendungen von Gentherapien limitiert. Virale Vektoren 
zählen zu den effizientesten Transfermethoden von Nukleinsäuren in Zellen. Aufgrund der 
erheblichen Nebenwirkungen, welche die Anwendung von Viren verursacht, wurden in der 
letzten Jahrzehnten die unterschiedlichsten nicht-viralen Methoden entwickelt. Obwohl einige 
nicht-virale Methoden für den Gentransfer bereits in klinischen Studien (Phase I und II) getestet 
werden, ist ihre Effizienz geringer im Vergleich zu den viralen Ansätzen. Daher muss es Ziel 
der Forschung sein, verträgliche und wirksame Systeme für den Gentransfer zu entwickeln um 
nachhaltig den Erfolg in der Gentherapie zu sichern.  
Der Fokus dieser Arbeit lag auf der Weiterentwicklung eines magnetischen Nanopartikel-
basierten Systems für den Gentransfer, welches zuvor in unserer Forschungsgruppe entwickelt 
wurde. Dieser nicht-virale Vektor basiert auf kationischen Polyplexen bestehend aus Plasmid-
DNA (pDNA) und Polyethylenimin (PEI), welche kovalent an magnetische Eisenoxid-
Nanopartikel (MNP) gebunden werden. Die Vorteile dieses Systems sind: eine vereinfachte 
Herstellung, hohe Affinität zur Nukleinsäure, relativ hohe Effizienz und Sicherheit, sowie die 
Möglichkeit den Vektor zielgerichtet mit Hilfe eines externen Magnetfeldes zu lenken. Das 
Ziel dieser Arbeit war, die pDNA/PEI/MNP Komplexe für die Anwendung in klinisch 
relevante Zellen (humane mesenchymale Stammzellen, hMSC) zu optimieren. Zusätzlich 
sollte der intrazelluläre Mechanismus der MNP-basierten Transfektion untersucht, sowie die 
klinischen Perspektiven von MNP-basierten Gentherapien analysiert werden.  
Die Ergebnisse dieser Arbeit haben gezeigt, dass pDNA/PEI/MNP Komplexe eine 
effiziente und sichere Transfektion von Knochenmark-isolierten hMSC auch ohne Anwendung 
eines Magnetfeldes leisten können. Um die Unterschiede zwischen den 
Transfektionsmechanismen von Polyplexen und MNP-basierten Komplexen weiter zu 
erforschen, wurden umfangreiche Kolokalisationsstudien durchgeführt. Dafür wurden 
erstmalig alle drei Komponenten des Transfektionssystems (pDNA, PEI und MNP) mit 
fluoreszierenden Farbstoffen markiert und zu unterschiedlichen Zeitpunkten mittels konfokaler 
Laser Scanning Mikroskopie visualisiert. Die Analyse von Kolokalisationskoeffizienten zeigte, 
dass MNP-basierte Vektoren aufgrund eines effizienteren pDNA-Freisetzungsprozesses eine 
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II 
bessere Transfektionseffizienz im Vergleich zu Polyplexen besitzen. Diese Ergebnisse 
unterstreichen den Einfluss der Zusammensetzung des Vektors auf den Transfektionsprozess 
und seine Effizienz. Im Folgenden wurde niedermolekulares PEI (600 Da) genutzt um die 
Biokompatibilität des Transfektionssystems zu verbessern. Das neue System wurde 
charakterisiert und in COS-7 Zellen getestet. Obwohl der erstellte Vektor eine höhere 
Biokompatibilität und Sicherheit versprach, erzielte er nicht vergleichbare Effizienzen im 
Vergleich zu den Vektoren mit hochmolekularem PEI (25 kDa). Weitere Möglichkeiten die 
Biokompatibilität und Sicherheit von MNP-basierte Tranfektionssystems zu verbessern 
wurden in einer Übersicht über die neuesten Strategien in dieser Arbeit zusammengefasst.  
Schlussendlich wurde im Rahmen dieser Arbeit eine MNP-basierte nicht-virale 
Gentransfermethode für klinisch relevante Zellen (i.e. hMSC) entwickelt. In den in vitro 
Studien zum Transfektionsmechanismus konnten die Vorteile eines magnetischen 
Transfektionsvektors belegt werden. Zusätzlich gibt es eine Vielzahl möglicher 
Modifikationsstrategien um die Biokompatibilität von MNP-basierten 
Transfektionskomplexen zu verbessern. Dies ist eine wesentliche Grundlage für weitere 
Forschungsfortschritte. Dennoch sind für die klinische Entwicklung der Gentherapie und deren 
Translation in die Klinik weitere präklinische Studien erforderlich, wie etwa die Untersuchung 
der in vivo Verteilung der Transfektionskomplexe bzw. der Abbauprodukte.  
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Summary 
The recent progress in gene therapy gave hope to many patients with rare genetic diseases, 
cancer and cardiovascular disorders. However, the safety aspects of this approach still remain 
a big concern, which limits rapid development and clinical use of gene therapy based drugs. 
Although viral vectors provide the most efficient delivery of nucleic acids to cells, serious side 
effects related to their application have forced the development of nonviral gene delivery 
methods in the last decades. Some of these nonviral gene delivery methods have already 
entered phase I-II clinical trials, although their efficacy is still lower than that of viral vectors. 
Hence, the development of safe and efficient gene delivery systems is the key to the overall 
success of gene therapy.  
Current work was focused on a particular magnetic nanoparticle-based gene delivery 
system, developed previously by our group. This combined nonviral carrier system consists of 
polyplexes – plasmid DNA (pDNA), condensed by polyethylenimine (PEI) - which are 
covalently bound to the iron oxide magnetic nanoparticles (MNP). The beneficial properties of 
this system include ease of production, high affinity to nucleic acids, relatively high efficiency 
and safety as well as potential for targeted delivery due to magnetic compounds. This work 
aimed to optimize pDNA/PEI/MNP complexes for application in clinically relevant cells 
(human mesenchymal stem cells (hMSC)), to gain insights about the intracellular mechanism 
of MNP-mediated transfection and to evaluate the clinical perspectives of MNP-based gene 
therapy.  
The results of the current work showed that pDNA/PEI/MNP complexes can efficiently 
and safely transfect bone marrow derived hMSC even without application of a magnetic field. 
To further study the differences in transfection mechanisms between polyplexes and MNP-
based complexes, extensive colocalization studies were performed. To this end, for the first 
time, all three components of the transfection system (pDNA, PEI and MNP) were selectively 
labelled with fluorescent dyes and visualized by confocal laser scanning microscopy at 
different time points. The analysis of colocalization coefficients demonstrated that the MNP-
based carrier provided better transfection efficiency due to more efficient release of pDNA in 
comparison to polyplexes alone. This finding emphasized a strong influence of the carrier 
composition on transfection processes and the efficacy. Next, aiming to increase the 
biocompatibility of the studied transfection system, PEI with low molecular weight (600 Da) 
was used. The system was characterized and tested in COS-7 cells. While the designed system 
Summary 
 
  
 
IV 
was rather safe, it could not outperform the original composition with high molecular weight 
PEI (25 kDa). Therefore, an overview of the recent strategies for improvement of 
biocompatibility properties and safety profile of MNP-based transfection systems 
complemented this work.  
In conclusion, this work introduced a MNP-based nonviral gene delivery approach that 
could be of use for clinically relevant cells (i.e. hMSC). The in vitro mechanism studies 
explained the beneficial properties of the proposed carrier design. The variety of modification 
strategies to improve the biocompatibility of this system provides a firm basis for further 
research progress.  Nevertheless, thorough preclinical studies, including investigations on the 
in vivo biodistribution of transfection systems and their components will be essential for further 
clinical development and translation.  
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1 Introduction 
1.1 From genetic modifications in bacteria to gene therapy in humans 
1.1.1 Genetic engineering  
Everyday, various kinds of genetic modifications (also termed genetic engineering) are 
easily performed in every research lab all over the world. Many experiments, i.e. bacteria 
transformation, transduction, transfection, gene knockout, reporter gene expression, together 
with genetically engineered animal models became a routine, although deoxyribonucleic acid 
(DNA) has become a topic of intense research since less than 70 years ago. The aim of genetic 
engineering is to modify the genome of an organism by artificial means. The first discoveries 
in bacterial genetics by F. Griffith [2], J. Alloway [3, 4], O. Avery [4], N. Zinder [5], E. Tatum 
and J. Lederberg (Nobel Prize winners in 1958) [6], including the work of J. Watson and F. 
Crick on a DNA structure in 1953 [7] (Nobel Prize winners in 1962) evoked a great interest in 
this field [8]. Already in 1976, H. Boyer and R. Swanson founded the first genetic engineering 
company Genentech. Following the breakthrough of H. Boyer and S. Cohen in recombinant 
DNA technology [9], the company focused on the production of human hormones using 
genetically engineered bacteria (somatostatin, insulin, growth hormone) [10]. 
Nowadays, genetic engineering is widely used in industrial production of medicines (e.g. 
hormones, vaccines, monoclonal antibodies), basic research and agriculture. Gene therapy is 
one of the most important and challenging fields, where genetic modifications play a key role.  
1.1.2 Gene therapy: history and clinical progress 
Gene therapy is an experimental technique, aiming to cure or treat the disease by 
introduction or alteration of genetic material within a cell or organism. The gene therapy of 
reproductive or germline cells is defined as germline gene therapy. The main risk of germline 
gene therapy is that it can change the genetic make-up of the patient and can be passed onto 
offspring of the patient. Therefore, due to unresolved ethical issues regarding human germline 
gene therapy, no approved applications of this form of treatment exist [11]. All further 
discussion about gene therapy in this work will focus on somatic gene therapy, which affects 
gene expression of the cells that will be corrective to the organism, but not inherited.  
The first understanding that genetic modifications could serve for the treatment of genetic 
disorders appeared in late 1960s, when it became apparent that viruses might be of use for gene 
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delivery. In 1968, S. Rogers and P. Pfuderer showed “proof-of-principle” of virus-mediated 
gene transfer using a tobacco mosaic virus [12]. However, the new findings raised many 
concerns. M. Fox and J. Littlefield in their editorial, published in Science in 1971, discussed 
the hazards and limitations of viral approach for gene therapy. They emphasized the safety 
issues of viral vectors (mutagenesis and tumorigenesis), and doubted their efficiency (the 
inability of a small population of genetically modified patient cells to completely cure the 
disease) [13]. Yet, since 45 years, a great progress in gene therapy field has been made, though 
the main concerns remain the same.  
The first clinical trials, aiming to evaluate the safety of gene therapy were carried out in 
1990s. S. Rosenberg, for instance, performed clinical trials on patients with metastatic 
melanoma [14]. M. Blaese and C. Bordignon were independently working on adenosine 
deaminase (ADA) deficiency [15, 16]. M. Cavazzano-Calvo reported restored immunity in 
patients with X-linked severe immunodeficiency after the application of hematopoietic cells, 
transduced with a retroviral vector [17]. Although, the results were not always as good as 
expected, gene therapy in general experienced a boom until the death of Jesse Gelsinger in 
1999 [8, 18]. The trial of M. Batshaw and J. Wilson in 1999 included the worst case of 
unsuccessful gene therapy, where for the first time the side effect was directly related to the 
viral vector [19]. The study aimed to evaluate the safety of adenovirus, carrying recombinant 
complementary DNA (cDNA), in patients with ornithine transcarbamylase deficiency. Due to 
severe immune response, that caused a multiorgan failure, the 18-years old patient died 4 days 
after the treatment. This tragedy raised up such issues as non-compliance with the study 
protocol and underreporting of adverse events, which led to the reduction of efforts and 
resources, invested in gene therapy in the next years [1].  
The shift of research focus towards development of novel vectors for gene therapy, 
combining low immunogenicity with efficient delivery, led to a number of successful studies, 
reported in the last decade. For instance, a positive dynamic was observed in the treatment of 
malignant brain tumors, lipoprotein lipase (LPL) deficiency, Parkinson’s disease, severe heart 
failure, Leber's congenital amaurosis, β-thalassemia, haemophilia B, Wiskott-Aldrich 
syndrome and severe combined immunodeficiencies (SCID) [1]. Finally, in 2012 the first 
approved gene therapy drug appeared on the market. After a long and tortuous approval process 
Glybera® (alipogene tiparvovec) was recommended by the European Medicines Agency 
(EMA) for the treatment of adults with LPL deficiency – a rare monogenic disease. The active 
substance of Glybera® is a modified adeno-associated virus (AAV), engineered to express the 
LPL gene in the muscle tissue [20]. Another gene therapy approach has been just recently 
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(April, 2016) recommended by the Committee for Medicinal Products for Human Use (the 
authority of the EMA) for marketing authorisation. Strimvelis™ is a medicinal product, 
developed by Italian researchers and GlaxoSmithKline Trading Services (Ireland) for the 
treatment of a very rare indication - ADA–SCID in children. It includes autologous CD34+ 
cells transduced with a retroviral vector encoding for the human ADA cDNA sequence [20, 
21]. However, the regulatory process, which led to the approval of Glybera®, included several 
reapplications and reexaminations of the drug, thus highlighting the prolonged and challenging 
regulatory pathway of gene therapy products in the European Union (EU) [22, 23].  
To date, over 2350 clinical trials involving genetic modifications are approved, ongoing or 
completed in 36 countries all over the world. Although initially gene therapy was thought to 
treat genetic diseases, most of the reported clinical trials were dedicated to cancer treatment 
(64.4%) [24]. The reasons for that are scientific advances in selective tumor targeting by 
genetic vectors, that can be reached by a number of methods [25]. However, of more than 6000 
inherited diseases known to date, very few can be treated by supplying a missing or defective 
gene product exogenously. For many other monogenic diseases, gene therapy might be the 
most successful approach. To date, only 235 clinical trials address their treatment to monogenic 
diseases (10%) [24]. The key to successful development of effective and safe gene therapy 
products is an appropriate selection and optimization of gene delivery methods.  
1.2 Gene therapy methods 
Gene therapy can be performed directly (in vivo) or indirectly (ex vivo). The first approach 
comprises direct delivery of the gene of interest to the target organs or tissues in the organism 
(e.g. via systemic or local injection). The indirect approach or cell-based gene therapy includes 
two steps: gene delivery to the cells, previously isolated from patient or donor, and further 
transplantation of transfected/transduced cells to the target site [26]. Both, in vivo and ex vivo 
applications have their advantages and drawbacks. Thus, the outcome and side effects of direct 
gene therapy depend on the administration way. The success of cell-based gene therapy is 
strongly related to the type of selected cells and their migration and proliferation properties. 
Moreover, the selection of the appropriate method for gene delivery is a very crucial step in 
both cases. It very much defines efficacy, selectivity and safety of the therapy. Kaestner et al. 
have recently discussed the technical aspects of mostly used gene delivery methods [27]. They 
also proposed a guideline for selecting a method of gene transfer in eukaryotic cells both, in 
vitro and in vivo. The authors admit, that the general recommendation is difficult, but their 
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guideline might help the researches, seeking the optimal gene delivery method for their 
experiments and support them in developing novel transfection techniques in placing their 
method correctly in the context of applications [27].  
The overview of the methods, utilized for gene delivery in clinical trials is shown in Figure 
1.1. Different types of viruses represent the major part of them (67%), while nonviral methods 
are used just in 22% of reported clinical trials [24].  
 
The next sections of this chapter will thoroughly describe the advantages and limitations of 
both, viral and nonviral methods, focusing on their current or potential clinical applications.  
1.3 Viral gene delivery: methods and clinical applications 
Virus-mediated gene delivery was initially a method of choice for gene therapy due to high 
efficiency. Viruses are perfect gene delivery systems created by nature. Once scientists had 
realized that, they tried to use the natural viral properties for the goals of medicine. A 
comprehensive review on viral gene delivery and its clinical outlook has been recently 
published by Kotterman et al. [1]. Table 1.1 summarizes several application examples of viral 
vectors, used in gene therapy in the last decade.  
Adenoviruses represent 21.7% of all gene delivery methods used in clinical trials (Fig. 
1.1), as they provide a very high transduction efficiency in vivo. However, they were shown to 
be highly immunogenic and provide only a short-term transgene expression [68]. 
 
Figure 1.1: Overview of the methods, utilized in gene therapy clinical trials worldwide. 
Retrieved from http://www.abedia.com/wiley/ [24]. 
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Therefore, adenoviral vectors are now widely used in therapies requiring initiation of 
immune response (cancer treatment) and as a platform for developing vaccines. Due to their 
short-term expression adenoviruses have also a potential for applications where new formation 
of biologic structures is required (e.g. angiogenesis) [1].  
 
Retroviruses and lentiviruses represent another big group of viral vectors utilized in the 
clinic (23.9%). Both of them are integrating into the host genome and have been successfully 
used in clinical trials involving ex vivo hematopoietic gene delivery. However, retrovirus-
mediated gene delivery is related to insertional mutagenesis, challenging its safety. In order to 
Virus Indications Approach Reference 
Retrovirus  
(murine leukemia) 
ADA-SCID Ex vivo [28] 
Lentivirus 
(self-inactivaing) 
ß-thalassemia Ex vivo [29] 
Leukodystrophy [30, 31] 
Wiskott-Aldrich Syndrom [32] 
Leukemia [33-35] 
Adenovirus Vaccines against HIV, malaria, 
tuberculosis, influenza 
In vivo [36-41] 
Coronary artery disease [42] 
Cancer therapy (glioma, B-cell 
lymphoma) 
[43, 44] 
Adeno-associated virus Heamophilia B In vivo [45, 46] 
Rheumatoid arthritis [47] 
Cystic fibrosis [48] 
Lipoprotein lipase deficiency [49-51] 
Leber’s congenital amaurosis [52-54] 
Choroideremia [55] 
Muscular dystrophy [56, 57] 
Severe heart failure [58] 
α-1-Antitrypsin deficiency [59, 60] 
Parkinson’s disease [61-63] 
Herpes simplex virus Malignant melanoma In vivo 
(intratumoral) 
[64] 
Vaccinia virus Liver cancer, metastatic tumors In vivo 
(intratumoral) 
[65-67] 
Table 1.1: Viral vectors most recently used in gene therapy clinical trials worldwide (Phase I/II) and their clinical 
applications (years 2005-2015). The data are taken and modified from [1]. 
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decrease these risks, self-inactivating lentiviruses were developed and applied in T-cell therapy 
of leukemia, hematopoietic stem cell therapy of ß-thalassemia, etc. [1, 29, 35]. 
 
In parallel, the development of adeno-associated viruses (AAV) in the last decade, which 
represent just 6.7% of viral vectors in clinical trials, led to an increasing number of successful 
studies worldwide, including Glybera® approval. Recently, AAV were widely used for the 
treatment of different monogenic diseases (Table 1.1), showing a strong safety profile, 
persistent gene expression and therapeutic benefits [1].  
 
However, safety of viruses remains the major concern for clinicians. The main risks include 
insertional mutagenesis (also called genotoxicity), oncogenesis and immunogenesis. 
Moreover, the production of virus-based delivery systems requires high costs and is not always 
feasible at high titers. The capacity to load the required amount of transgenic material is also 
limited for most viruses. Although a big progress in understanding the transduction 
mechanisms has been made, and novel viral vectors are nowadays more selective and 
significantly safer than those, developed 20 years ago, many researches are seeking for an 
“ideal” gene delivery method among the nonviral strategies.  
1.4 Nonviral gene delivery: methods and clinical applications 
Aiming to minimize the side effects of gene therapy with no loss in efficiency, various 
nonviral methods were developed and investigated in the last decades. The reviews of Al-
Dosari et al. [69], Wang et al. [70], Schlenk et al. [71] and Jin et al. [72] comprehensively 
describe the recent progresses on nonviral systems for gene delivery. Table 1.2 shows nonviral 
carriers, recently evaluated or currently involved in clinical trials.  
 
 
Nonviral agent Indications Approach Reference 
Naked DNA Cancer therapy In vivo [24, 73] 
Cardiovascular diseases 
Critical limb ischemia 
Electroporation Metastatic melanoma In vivo  [74, 75] 
Hydrodynamic gene 
transfer 
Liver cirrhosis with 
thrombocytopenia  
In vivo  [24, 76] 
GNE - myopathy 
Table 1.2: Nonviral vectors, most recently used in gene therapy clinical trials worldwide (Phase I/II/III) and their 
clinical applications (years 2005-2015). 
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Nonviral agent Indications Approach Reference 
Cationic lipids Advanced metastatic melanoma  In vivo [77, 78] 
[79] Cystic fibrosis 
 
All nonviral transfection methods can be divided into two groups: physical and chemical 
methods.  
1.4.1 Physical methods for gene delivery  
Physical methods are using naked nucleic acids, which are mechanistically delivered to the 
cell via microinjection, gene gun, electroporation, sonoporation, optical transfection and 
hydrodynamic gene transfer. These methods might be aggressive for cells as they involve 
physical damage of the cell membrane, even though it is not a permanent state. Moreover, 
naked nucleic acids, delivered into the cytosol, undergo a high risk to be destroyed by 
nucleases. Therefore the level of transgene expression is usually low and the effect is short-
term [69, 70]. However, the physical approach is easy to use as it does not require any complex 
biological structures or chemicals to be produced, and does not lead to an immune response of 
the organism. Moreover, the delivered gene can be easily “tuned” by standard recombinant 
DNA techniques [80].  
Microinjection is a direct ejection of genetic material into the nucleus of the target cell 
under observation. This method of gene transfer must be trained in advance and is useful when 
only a limited number of cells should undergo genetic modification [27]. Microinjections have 
been widely used in preparation of transgenic animals, in vitro fertilization and studies of 
primary cells and ribonucleic acid (RNA) interference [81]. However, this technology cannot 
be scaled up for direct in vivo applications and is not able to transfect the necessary amount of 
cells for indirect gene therapy approach. Compared with other physical methods for gene 
delivery, microinjection is the least feasible for clinical use. 
Gene gun technique (or ballistic gene delivery) includes heavy metal particles, carrying 
DNA on their surface, which are delivered to the cells by a pressurized inert gas [82]. Already 
in the middle of 90’s this technology was applied for immunomodulation therapy in melanoma 
patients [83, 84]. Naked DNA has entered the clinical trials in 2000. It was used as a vector 
for intramuscular delivery of growth factors in limb ischemia patients [85, 86]. Up to now, 
naked plasmid DNA (pDNA) alone has been used as a vector in 422 clinical trials worldwide 
(17.4% of all gene delivery methods), mainly focused on cancer therapy and cardiovascular 
diseases [24].  
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The first clinical trials involving in vivo electroporation were carried out in 2005 aiming 
to investigate the safety and efficacy of interleukin – encoding pDNA delivery in treatment of 
metastatic melanoma [74, 75]. Electroporation requires at least two electrodes, connected to a 
power supply, that enclose a target tissue (in vivo) or cell suspension (in vitro). The electrical 
impulses lead to the temporary formation of pores in the cell membrane, thus enabling DNA 
to enter the cell [82]. A similar principle of nucleic acid delivery via transiently formed pores 
is utilized by sonoporation and optical transfection methods, by the means of ultrasound or 
laser light stimulation, respectively. In combination with DNA-loaded microbubbles 
sonoporation technology has been shown to provide efficient gene transfer in vitro and in vivo 
[87]. Optical transfection with femtosecond laser was able to provide safe, selective and 
localized gene delivery in mammalian cells [88].  
Hydrodynamic gene transfer employs a rapid intravenous injection of a large volume of 
pDNA solution, which allows the entry of DNA through the pores in capillary endothelium. 
This method has been broadly applied aiming to deliver DNA, RNA, proteins or synthetic 
compounds in various tissues [82]. For instance, in 2008 this method was used in clinical trials 
of hydrodynamic delivery of thrombopoietin to the liver of cirrhotic patients with 
thrombocytopenia [76]. A phase I clinical trial for the initial evaluation of safety and efficacy 
of hydrodynamic transfer of a gene encoding the enzyme for the biosynthesis of sialic acid 
(Glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosamine kinase, or GNE gene) into 
a limb vein of patients with GNE – myopathy has been initiated in 2013 [24]. 
  
To date, physical gene delivery methods are mostly applied in the production of DNA – 
vaccines for cancer therapy, which are involved in several Phase I-II clinical trials [24]. Various 
phase II clinical trials involving naked pDNA, encoding growth factor genes for the gene 
therapy of cardiovascular diseases are also underway [24]. After successful safety studies, a 
hepatocyte growth factor encoding plasmid (intramuscular injections) has entered the Phase III 
clinical trials of critical limb ischemia [73, 89]. 
1.4.2 Chemical methods for gene delivery 
Chemical methods for gene delivery include gene delivery using cationic lipids, cationic 
polymers and dendrimers, synthetic peptides, inorganic nanoparticles, and combined vectors. 
Here, the transported nucleic acid is condensed by the carrier and therefore protected from 
intracellular degradation, which is of advantage in comparison to physical methods. 
Additionally, the synthetic origin of the above listed nonviral carriers allows chemical 
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modifications for the adjustment of chemical and physical properties of the delivery system 
[71].  
Whereas viruses have already actively entered the clinical research, nonviral carriers just 
start their journey from bench to bedside. However, many chemical transfection agents were 
already commercialized (Table 1.3). A large amount of published articles reporting the 
development of novel nonviral systems and their pre-clinical investigations indicate a great 
potential of this approach.  
 
Transfection agent Company Country 
Cationic lipids 
Lipofectin®, Cellfectin®, Optifect™, 
DMRIE-C Transfection Reagent, 
Lipofectamine® family 
Thermo Fischer 
Scientific 
Waltham, MA, USA 
FuGENE®, TransFast™ Promega Madison, WI, USA 
Attractene, Effectine, HiPerFect 
TransMessenger 
QIAGEN Venlo, Netherlands 
Escort™ Sigma-Aldrich St. Louis, MO, USA 
DreamFect™ , Lullaby siRNA OZ Biosciences Marseille, France 
GenePORTER®, PerFectin™ Genlantis San Diego, CA, 
USA 
TurboFectin 8.0™ OriGene Rockville, MD, USA 
Cationic polymers 
X-tremeGENE™ Sigma-Aldrich St. Louis, MO, USA 
jetPEI®, jetPRIME® Polyplus-transfection® Illkirch, France 
TransIT-X2® Dynamic Delivery 
System 
Mirus Bio® LLC Madison, WI, USA 
Xfect Transfection reagent   Clontech Laboratories, 
Inc. 
Mountain View, CA, 
USA 
Magnetic nanoparticles 
Magnetofectamine™, PolyMag, 
LipoMag, CombiMag, NeuroMag, 
SilenceMag 
OZ Biosciences Marseille, France 
nTMag, nTMag Plus nanoTherics Ltd Newcastle under 
Lyme, UK 
 
1.4.2.1 Cationic lipids 
To date, cationic lipids represent the most successful group of nonviral carriers in terms of 
clinical applications. To date, many efficient cationic lipid-based transfection reagents were 
commercialized (Table 1.3). 
Table 1.3: Examples of chemical carriers for transfection, currently available on the market. 
CHAPTER 1. Introduction 
 
  
 
10 
In general, lipid-based transfection reagents are composed of cationic lipids (e.g. N-[1-(2, 
3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP), 1,2-
dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE), etc.) mixed 
with helper (or neutral) lipids (e.g. dioleolyphosphatidylethanolamine (DOPE)) or cholesterol. 
Cationic lipids are characterized by a hydrophobic tail, a positively charged hydrophilic head 
group (usually consisting of quaternary ammonium salts) and a linker. These mixtures are able 
to condense negatively charged nucleic acids, forming positively charged (at physiological pH) 
liposomes or micelles – lipoplexes. The lipoplexes can easily enter the cell via endocytosis and 
further process the delivered nucleic acid [90, 91]. The variety of lipid-based transfection 
reagents nowadays allows scientists to select the optimal reagent for their experiments. Thus, 
lipid-based transfection systems have been explicitly optimized for the delivery of pDNA, 
RNA, small interfering (siRNA), microRNA (miRNA) or oligonucleotides. Transfection 
protocols have been adjusted for different cell types, including suspension and adherent cell 
cultures, as well as primary and “difficult-to-transfect” cells [92]. The main advantages of 
cationic lipids as transfection reagents include good biocompatibility, low immunogenicity, 
high load of delivered nucleic acids and ease in use and preparation [72]. Moreover, various 
possible chemical modifications of the lipid structure may allow gaining biodegradable 
properties and improving transfection efficiency, stability and safety of the lipid-based gene 
delivery systems.  
Cationic lipids have entered the clinical trials already in 1993, when Nabel et al. performed 
the first direct gene delivery study in humans. They used DMRIE/DOPE for the direct 
intratumoral delivery of a gene, encoding foreign major histocompatibility complex class 1 
(MHC 1) protein (human leukocyte antigen serotype B7 (HLA-B7) gene), in HLA-B7-negative 
patients with stage IV melanoma. The study showed the feasibility, safety, and therapeutic 
potential of direct lipid-based gene transfer [93, 94]. Further, the lipoplexes consisting of 
DMRIE/DOPE and genes for MHC 1 protein (HLA-B7 and beta-2-microglobulin) have 
undergone phase I, II and III clinical trials as Allovectin-7 or later, Allovectin® (a registered 
trademark of Vical Inc., San Diego, California, USA). Despite the promising phase II study 
results [77, 78], the company had to discontinue the phase III clinical trials, as Allovectin® 
failed to show an improvement compared with chemotherapy at primary and secondary 
efficacy endpoints [95]. Another indication, where cationic lipids reached the clinical 
application is cystic fibrosis. Since the middle 90s’ several research groups have independently 
performed phase I and II clinical trials, where cDNA, encoding a cystic fibrosis transmembrane 
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regulator gene (CFTR), was delivered by cationic lipids into nasal epithelium of patients [79, 
96-101]. These studies reported that the treatment was safe, but the transgene expression levels 
were not high enough in order to achieve a therapeutic effect [99, 101]. According to the Gene 
Therapy Clinical Trials Database, a number of similar clinical trials involving CFTR gene has 
been initiated in the last 5 years, though no data on the outcomes of these studies are available 
yet [24]. 
Despite the recent progress, cationic lipid-based transfection reagents still possess several 
limitations. These include low stability in the bloodstream, low specificity and cytotoxicity 
related to the cationic nature of the head group [72, 102]. It has also been shown that cationic 
lipids and pDNA have a synergism in causing cytotoxicity, thus formation of lipoplexes can 
lead to cell death via apoptosis in vitro [103] and even activate an immune response in vivo 
[104]. Therefore, cationic lipids to date remain the method of choice for transfection in 
experimental settings, and require further improvement of safety and efficacy to proceed in the 
clinic. 
1.4.2.2 Cationic polymers and dendrimers 
Cationic polymers represent another big group of chemical methods for transfection. They 
include various polyamines and their numerous derivatives. Poly(L-lysine) (PLL), 
polyethylenimine (PEI), and chitosan are the mostly used and investigated cationic polymers 
for gene delivery (Fig. 1.2).  
Numerous reviews and book chapters address their issues to the variety of cationic 
polymers used nowadays for gene delivery. This group of polymers gained the attention of 
researches due to its physical and chemical properties, that make cationic polymers a promising 
tool for gene delivery. Cationic polymers are characterized by their high positive charge 
(usually provided by numerous aminogroups). Via electrostatic interactions with negatively 
charged phosphate groups they easily condense nucleic acids and form stable complexes – so 
called “polyplexes”. Due to a strong positive surface charge, polyplexes attach to the cell 
membrane and enter the cell via endocytotic pathway, followed by endosomal escape and the 
release of nucleic acid in the cytosol [105].  
Initially, lipopolyamines and polyamidoamines were tested as gene delivery agents in the 
90s’ [106-108]. PLL was also among the “pioneers” in polymer-based gene delivery. Due to 
its peptide structure, the polymer is biodegradable, which makes it an attractive tool for in vivo 
applications. 
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However, the toxicity of PLL does not allow to use it for efficient and safe gene delivery 
[109].  
PEI, that later became “a gold standard” for nonviral gene delivery, for the first time was 
used by Boussif et al. in 1995 [110]. An extensive review on the recent progress in the 
development of PEI-based gene delivery systems has been published by Wang et al. [111]. PEI 
has a very high density of amines, as its structure combines primary, secondary and tertiary 
aminogroups (Fig. 1.2). This feature plays a key role in the efficient delivery of nucleic acids 
with PEI. Due to the following properties, PEI has remained in the focus as the most promising 
gene delivery agent in the last decades [111]:  
 Efficient condensation of nucleic acids of different size; 
 Enhancement of cellular uptake of polyplexes due to their positive charge; 
 Protection of delivered nucleic acids from enzymatic degradation; 
Figure 1.2: Chemical structures of cationic polymers and dendrimers 
mostly used as gene delivery carriers. Retrieved and modified from 
http://rsif.royalsocietypublishing.org/ [105]. 
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 Exceptional buffering capacity under acidic pH, which facilitate the endosomal 
escape of polyplexes due to the “proton sponge effect”1 [112]. 
Although PEI alone has demonstrated a high transfection efficiency in vitro and in vivo, 
viral gene delivery remains the most effective approach [113]. Moreover, PEI applications are 
limited due to high cytotoxicity and low biocompatibility of the polymer. PEI was shown to 
cause membrane damage due to strong electrostatic interactions and apoptosis due to 
mitochondrial alterations in clinically relevant human cell lines [114, 115]. Therefore, in order 
to reduce toxicity and improve transfection efficiency, much research has been recently 
devoted to the development of novel carriers on the basis of PEI or other cationic polymers. 
PEI with molecular weights (MW) from 600 to 2000 Da, for example, demonstrated much 
lower cytotoxicity as PEI with MW of 25 kDa used initially. However, these low-molecular 
weight (LMW) polymers alone did not provide the desired transfection efficiency [116].  
Naturally-derived cationic polymers, including chitosan, has also been shown to have a 
strong affinity to DNA, providing good transfection rates and low cytotoxicity [117]. 
Moreover, they are biodegradable and biocompatible, thus possess a great potential as in vivo 
gene delivery vectors. In order to improve their transfection efficiency and specificity, many 
chemical modifications have been performed and described elsewhere [117]. 
Dendrimers are spherical, highly brunched three dimensional polymers, characterized by 
high density of amines at the periphery of the macromolecule [118]. The most widely used 
dendrimers for transfection approaches are poly(amidoamines), or PAMAM, which have 
already been commercialized as Polyfect® and Superfect® by QIAGEN (Venlo, Netherlands). 
Despite many in vitro and in vivo studies of these agents, their clinical translation is not feasible 
due to low transfection efficiency [109].  
In the last decade numerous strategies for the modifications of cationic polymers and 
dendrimers were performed and characterized in terms of toxicity and transfection efficiency 
both, in vitro and in vivo. For instance, coating of cationic polymers with hydrophilic 
polyethylene glycol (PEG) can improve their pharmacokinetics and stability in the bloodstream 
by hindering interaction with serum proteins [119]. Modification of polymers with 
hydrophobic (alkanes, fatty acids, phospholipids) moieties improve condensation of nucleic 
acids and their intracellular trafficking, and reduce cytotoxicity of the carrier. Additionally, the 
                                                 
1 The hypothesis of “proton sponge effect” has recently been argued as no changes in lysosomal pH, related to 
the polyplexes, were observed. Thus, the amount of PEI, DNA or polyplexes, escaping the 
endosomes/lysosomes must be low, but enough for efficient transfection. 
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selectivity and targeting of cationic polymers – derivatives can be reached by adding of stimuli 
responsive groups and targeting ligands [120]. The variety of polymer-based nanocarriers, in 
general, can be characterized by efficient gene transfection, low cytotoxicity, capability to co-
deliver nucleic acids and chemotherapy drugs, ease of modification with targeting molecules, 
and good responsiveness to external stimuli [105]. 
Despite the promising findings and rapid development of cationic polymer-based 
transfection systems, none of them has been applied for gene therapy in humans yet.  
1.4.2.3 Synthetic peptides 
The application of synthetic peptides, e.g. cell penetrating peptides (CPPs), for gene 
delivery is currently rapidly growing. These cationic or amphipathic peptides are able to 
condense nucleic acids, enter the cells without toxic effects and carry the cargo into live cells, 
although the mechanisms of their internalization are not clear, yet [121, 122]. CPPs have been 
mostly used in combination with viral or nonviral vectors, aiming to overcome the barriers for 
gene delivery [121].  
1.4.2.4 Inorganic nanoparticles 
Inorganic nanoparticles (InNP) for gene delivery represent a big group of nanosized 
structures of inorganic origin (normally ≤100 nm in diameter), which are able to transfer 
various genetic materials into the cell. They include gold, silica, iron oxide nanoparticles, 
quantum dots, carbon derivatives (e.g. carbon nanotubes) and calcium phosphate nanoparticles 
[123]. InNP possess several features that make them attractive for research and development 
of the carriers for gene transfer:  
 Easy preparation; 
 Wide availability; 
 High functionality; 
 Biocompatibility and biodegradability (e.g. silica and calcium phosphate 
nanoparticles); 
 Ability for broad characterization and different modifications; 
 Ability for controlled release of delivered nucleic acids (e.g. silica, gold and 
carbon nanostructures); 
 Ability to be monitored and guided in vivo (e.g. quantum dots and iron oxides). 
Due to the above listed properties and the variety of InNP, many advanced strategies for 
the delivery of nucleic acids have been developed and investigated in the recent years. These 
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strategies have been recently described by Voronina et al. in a comprehensive review, covering 
this topic [123]. 
Interestingly, the most successful InNP-based transfection systems were produced as 
combined vectors, containing different chemical carriers in order to merge their benefits. For 
example, gold and silica nanoparticles as well as carbon nanotubes were combined with 
cationic polymers; calcium phosphate nanoparticles were combined with cationic lipids and 
targeting moieties [123]. Iron oxide nanoparticles were combined with viral agents, cationic 
lipids and cationic polymers [124].  
Gene delivery systems, based on iron oxide nanoparticles require an extensional attention 
due to their broad application as transfection agents. Due to magnetic properties, they enable 
magnetic targeting – one of the most advanced and broadly studied technologies in gene 
delivery, which will be discussed in the next section of this chapter.  
1.5 Magnetic targeting in gene delivery 
At first, magnetic targeting was applied for site-specific delivery of drugs in cancer 
chemotherapy in the 1970s. For that purpose cytotoxic drug - loaded magnetic nanoparticles 
were guided to the target site by an external magnetic field [125, 126]. Several studies, 
performed in the following 30 years, showed that this approach was able to provide a local 
treatment with minimized side effects, and therefore attracted attention in other application 
fields, e.g. gene delivery.  
Since the first application of magnetic nanoparticles (MNP) in gene delivery in 2001 [127], 
they have been widely applied in combination with viruses, cationic polymers and cationic 
lipids [124].  
Christian Plank with colleagues at the Technical University of Munich were the pioneers 
in the field of magnetically - targeted gene delivery. For the first time their strategy, called 
magnetofection, was reported in 2002 by Scherer et al. They associated different gene delivery 
carriers (viruses, cationic lipids, cationic polymers) with superparamagnetic iron oxide 
nanoparticles (9-11 nm) and further attracted them by magnetic field gradients to the target 
cells [128]. This approach was later commercialized as Magnetofection™ (OZ Biosciences, 
Marseille, France) and was adjusted for transfection of various cell types, including primary 
and hard-to-transfect cells [129]. The group of J. Dobson has later proposed an application of 
oscillating magnetic fields aiming to improve transfection efficiency of magnetofection by 
additional lateral motions of MNP-based transfection reagents [130, 131]. This approach has 
also been commercialized under the name of Magnefect™ (NanoTherics Ltd, Newcastle under 
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Lyme, UK) [132]. The technique has recently been used by Subramanian et al. for delivery of 
enhanced green fluorescent protein plasmid (pEGFP) into human prenatal cardiac progenitor 
cells and adult cardiomyocytes in vitro. In comparison to static magnetofection, cationic lipid 
reagents and electroporation, oscillating magnet-assisted transfection with NeuroMag 
(nanoTherics, Keele, UK) in this work showed higher efficiency and maintained high cell 
viability [133]. Similar studies have also been performed to successfully transfect human 
mesenchymal stem cells and human osteosarcoma fibroblasts with no effect on cell viability 
and cell functions [134, 135].  
Since the reports of Plank’s and Dobson’s groups, magnetic targeting has become a 
powerful technique to improve efficiency and to decrease side effects of gene delivery in vitro 
and in vivo. An extensive overview of viral and nonviral magnetic targeting strategies, 
developed recently and successfully used in gene delivery can be found in different reports 
[124, 136, 137].  
Most research groups utilize MNP with a magnetite (Fe3O4) core, as they are easy to 
produce and are well studied due to their wide applications in bioimaging [138]. Several MNP 
with an iron oxide core have already been approved by the Food and Drug Administration 
(FDA) for application in magnetic resonance imaging (MRI) (i.e. Resovist®, Feridex IV®, 
Feroheme®), and therefore are well studied regarding their metabolism, pharmacokinetics and 
safety profile [139, 140]. It has been demonstrated that the iron oxide core of these MNP is 
broken down into other forms of iron and afterwards incorporated into haemoglobin in newly 
formed erythrocytes. Moreover, no MNP – related toxicity was observed [140]. Importantly, 
MNP used for gene delivery are mostly paramagnetic or superparamagnetic, which allows them 
to remain non magnetic in the absence of a magnetic field. Therefore, the main advantages of 
these MNP include easy resuspension, slow sedimentation and uniform distribution in the 
suspension media [141]. 
To create a magnetic transfection system, various nucleic acid carriers or nucleic acids 
alone are attached to the MNP - core using molecular linkers or physical interactions, as shown 
in Figure 1.3. Depending on the final assembly, the diameter of the whole system may vary 
from 100 to 500 nm. Applying an external static or oscillating magnetic field, MNP-based gene 
delivery systems can be controlled and manipulated both, in vivo and in vitro. The benefits of 
such an approach in vivo arise from the local targeting on a tissue scale [124]. The recent study 
of Muthana et al. proved that a standard clinical MRI scanner is able to provide a real-time 
image – guided targeting of magnetically labelled cells to the desired tissues in the organism 
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[142]. In vitro, magnetic targeting improves sedimentation of the carriers on the cell membrane, 
thus enhancing the efficiency of gene delivery [143].  
 
Magnetofection™ has been successfully applied in a wide range of cell lines, hard-to-
transfect and primary cells. It was adapted to all types of nucleic acids (pDNA, siRNA, double-
stranded RNA (dsRNA), small hairpin RNA (shRNA), messenger RNA (mRNA), 
oligodeoxynucleotides), non-viral transfection reagents and viruses [129, 136]. The majority 
of iron oxide MNP, used for Magnetofection™ are coated with a cationic polymer (most often 
Figure 1.3: Different strategies used for the construction of MNP-based gene carriers, by means of molecular  
linkers (a) or physical interactions (b). Retrieved from http://www.futuremedicine.com/ [124]. 
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PEI), which allows an association of genetic material or transfection agent by salt – induced 
colloidal aggregation.  
Li et al. in 2008 described a similar design of a MNP-based transfection system, consisting 
of iron oxide nanoparticles, PEI and pDNA [144]. In contrast to complexes for 
Magnetofection™, pDNA in this system was firstly condensed by biotinylated PEI (forming 
“polyplexes”), and afterwards attached to streptavidin - coated MNP by biotin – streptavidin 
interactions (forming “magnetic polyplexes”) (Fig. 1.4). This system provided successful 
nonviral gene delivery to three different cell lines (COS-7, HEK 293 and NIH 3T3) and primary 
endothelial cells (HUVEC) in the presence of an external magnetic field. Moreover, the pilot 
in vivo study in mice showed that after a systemic injection in the tail vein magnetic polyplexes 
were able to induce a localized thoracic expression of both, reporter and therapeutic genes 
under guidance of a magnetic field [144].  
The study of Chertok et al. in 2010 has demonstrated the potential of PEI – modified iron 
oxide MNP to be magnetically guided to brain tumors after intra-carotid injection in rats. 
However, no drug/gene delivery experiments were performed in order to evaluate the 
efficiency of the investigated carrier [145].  
In 2012, streptavidin – coated MNP were used for viral gene delivery by Zhang et al. Their 
work demonstrated the feasibility of magnetically guided therapeutic delivery of vascular 
endothelial growth factor (VEGF) gene to the infarcted heart of rats by means of a viral 
approach. That study focused on a MNP-based adenoviral vector and addressed certain safety 
concerns due to observed immunogenicity [146]. 
Figure 1.4: Schematic structure of 
pDNA/PEI/MNP transfection complex. 
The system includes a paramagnetic 
streptavidin – coated iron oxide 
nanoparticle in the core and pDNA/PEI 
complexes (polyplexes), attached via 
streptavidin – biotin interactions to the 
surface. 
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To date none of the MNP-based gene delivery systems has been applied in the clinic and 
researchers are still attempting to improve this approach. Therefore, the work presented in this 
thesis was performed to address the mechanisms of MNP-based gene delivery and its 
perspectives in terms of clinical applications.   
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1.6 Aim of the study 
Despite the progress in the gene therapy field, this approach remains experimental. 
Although it showed promising outcomes in treatment of inherited disorders and several cancer 
conditions, the safety and efficacy of the methods are under strong consideration. Viral vectors 
were broadly used and investigated as gene delivery carriers due to the high transduction 
efficiency. However, the risks related to that therapy have only allowed its applications for the 
treatment of conditions, which have no other cures. Therefore, a wide range of nonviral 
methods for gene delivery has gained an attention of the researchers. Nevertheless, only few of 
them have reached the clinical trials (i.e. naked DNA and cationic lipids). 
In the last decades, many groups have reported various gene carriers, based on magnetic 
nanoparticles and/or cationic polymers. Some of them were commercialized and demonstrated 
good performance in laboratory use. The advantages of those systems include high affinity to 
nucleic acids, high efficiency, good safety, selectivity and potential for targeted delivery due 
to magnetic compounds.  
The work presented here was dedicated to a gene delivery system, where pDNA was 
condensed by cationic polymer (PEI) and afterwards covalently bound to iron oxide magnetic 
nanoparticles. For the first time, this carrier was reported by Li et al. in 2008. Afterwards, the 
quality of the complexes was improved and transfection protocol was re-optimized in COS-7 
cells. These data were published by our group in 2014. The current study was intended to 
further investigate this nonviral magnetic transfection system and discuss its potential for 
clinical applications. 
The particular aims were set as follows:  
1. To test the performance of the transfection system in clinically relevant cells 
(i.e. human mesenchymal stem cells (hMSC)); 
2. To study the mechanism of transfection with pDNA/PEI/MNP complexes with 
focus on intracellular localization and process of pDNA release; 
3. To perform pilot tests of magnetic polyplexes, including LMW PEI, aiming to 
improve the safety of this transfection system; 
4. To evaluate the potential of the transfection system for clinical applications, 
referring to the current progress of gene delivery methods and discuss the future 
perspectives of MNP-based transfection. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Cell culture media and supplements  
Dulbecco`s Modified Eagle Medium (DMEM) with 4.5 g/l glucose, 3.7 g/l sodium 
hydrogen carbonate and L-glutamine, phosphate-buffered saline (PBS) and Roswell Park 
Memorial Institute (RPMI) 1640 were purchased from PAN Biotech GmbH (Aidenbach, 
Germany). Mesenchymal Stem Cell Growth Medium (MSCGM) and were purchased from 
Lonza (Walkerswille, MD, USA). Recovery™ Cell Culture Freezing medium (CCFM) was 
obtained from Gibco (Carlsbad, CA, USA). Minimum Essential Medium alpha (αMEM) was 
obtained from Life Technologies. Trypsin, Ethylenediaminetetraacetic acid (EDTA), penicillin 
and streptomycin were procured from PAA (Coelbe, Germany). Fetal bovine serum (FBS) was 
obtained from HyClone (Logan, UT, USA). Bovine serum albumin (BSA) was obtained from 
Sigma-Aldrich (St. Louis, MO, USA). 
2.1.2 Labelling and staining reagents  
Label IT® Tracker™ Intracellular Nucleic Acid Localization Kit was purchased from 
Mirus (Madison, WI, USA). FluoReporter® Oregon Green® 488 Protein Labeling Kit was 
obtained from Molecular Probes (Eugene, OR, USA). Atto 565 dye was provided by ATTO-
TEC GmbH (Siegen, Germany). 4´,6-diamidino-2-phenylindole (DAPI) was purchased from 
Invitrogen (Carlsbad, CA, USA). FluorSave™ Reagent was obtained from Merck Millipore 
(Darmstadt, Germany). Alexa Fluor 488 donkey anti-goat Immunoglobulin G (IgG) and Alexa 
Fluor 488 donkey anti-mouse IgG secondary antibodies and Near-IR LIVE/DEAD® Fixable 
Dead Cell Stain Kit were purchased from Molecular Probes by Life Technologies (Eugene, 
OR, USA). 
2.1.3 Conjugated antibodies 
CD29-APC, CD44-PerCP-Cy5.5, CD45-V500, CD73-PE, CD117-PE-Cy7 antihuman 
conjugated antibodies were obtained from BD Bioscience (Heidelberg, Germany). CD105-
AlexaFluor 488 antihuman conjugated antibodies were obtained from AbD Serotec 
(Kidlington, UK). 
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2.1.4 Chemicals and different assays 
Branched PEI (MW = 25 kDa), LMW PEI (MW = 600 Da), 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and paraformaldehyde (PFA) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Sulfo-NHS-LC-Biotin linker and BCA Protein Assay 
Kit were obtained from Pierce (Rockford, IL, USA). Streptavidin MagneSphere® 
Paramagnetic Particles, Reporter Lysis Buffer and Bright Glo Luciferase Reporter Assay were 
purchased from Promega (Madison, WI, USA). Human Mesenchymal Stem Cell Functional 
Identification Kit was purchased from R&D Systems (Minneapolis, MN, USA). Plasmid DNA 
Purification Kit was obtained from Macherey-Nagel (Düren, Germany). 
2.1.5 Other reagents  
6x DNA Loading Dye and GeneRuler™ 1 kb DNA Ladder were purchased from Thermo 
Fisher Scientific Baltics UAB (Vilnius, Lithuania). Agarose was obtained from Biozym 
Scientific GmbH, Hessisch Oldendorf, Germany. Boric acid, NaCl, dimethyl sulfoxide 
(DMSO) and trisaminomethane (Tris) were obtained from Carl Roth (Karlsruhe, Germany). 
2.2 Cell culture 
2.2.1 COS-7 culture 
African green monkey kidney fibroblast-like cell line (COS-7) was purchased from 
American Type Culture Collection (Manassas, VA, USA). The complete growth medium for 
COS-7 cell culture included a base medium (DMEM with 4.5 g/l glucose, 3.7 g/l sodium 
hydrogen carbonate and L-glutamine), which was supplemented with 10% FBS, 100 U/ml 
penicillin and 100 μg/ml streptomycin. Cells were seeded in 75 cm2 flasks and maintained at 
37°C in a humidified 5% CO2 incubator. The culture medium was renewed 2-3 times per week. 
At a confluency of 80 - 90% cells were subcultured. For that, old medium was removed, cell 
layer was rinsed with PBS and Trypsin/EDTA solution (0.25% (w/v) trypsin and 0.53 mM 
EDTA) was added. After incubation at 37°C for 3-4 min, a cell culture medium was added to 
stop the reaction. Cell suspension was aspirated and transferred to a 50 ml tube for further 
centrifugation (300g, 10 min). Afterwards, the supernatant was discarded, the cell pellet was 
resuspended in fresh cell culture medium and seeded in the new flasks. The subculturing of 
COS-7 cells was performed at a ratio of 1:4 or 1:8.  
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2.2.2 hMSC isolation and culture 
hMSC were derived from human bone marrow following the procedure, previously 
described by Gäbel et al. [147]. Sternal aspirates for this study were obtained from patients 
during coronary artery bypass grafting at the Department of Cardiac Surgery (University of 
Rostock). All bone marrow donors gave the informed written consent to use their samples for 
experimental purposes. Mononuclear cells (MNC) were isolated by density gradient 
centrifugation (445 g, 35 min) of bone marrow aspirates in Leucosep® tubes (Greiner Bio-One 
GmbH, Solingen, Germany) with 15 ml of RPMI medium. Afterwards the interphase of MNC 
was collected and seeded in 175 cm2 flasks for further selection by plastic adherence in 
MSCGM, supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin. The culture 
was maintained at 37°C in a humidified 5% CO2 incubator. The medium was renewed every 
2-3 days. After cell colonies reached 70-80% confluency, hMSC were subsequently passaged 
or kept frozen in liquid nitrogen for long-term storage. The subculturing was performed at a 
ratio of 1:2 as described above for COS-7 cells. For freezing, a Recovery™ CCFM and Nunc® 
CryoTubes® (Sigma-Aldrich, St. Louis, MO, USA) were used. hMSCs of passage 3 were used 
in all experiments.  
2.3 Plasmids 
pEGFP-N3 plasmid, encoding EGFP under control of the cytomegalovirus (CMV) - 
promoter was obtained from Clonetech (Palo Alto, CA, USA). pcDNA3.1-Luc plasmid 
encoding firefly luciferase under CMV - promoter in pcDNA 3.1 vector (Invitrogen, Carlsbad, 
CA, USA) was a kind gift of Dr. Wenzhong Li (University of Rostock, Germany).  
For amplification, the plasmids were transformed in Escherichia coli DH5α-strain 
(Invitrogen, Carlsbad, CA, USA). Isolation and purification of both plasmids were performed 
using Plasmid DNA Purification Kit according to the manufacturer’s protocol. The 
concentration and purity of obtained pDNA were checked by measuring their absorbance at 
260 and 280 nm. Plasmids with 260/280 absorbance ratio of ~1.8 were considered as suitable 
for further experiments. Plasmids were stored in 5mM Tris/HCl (pH 8.5) buffer in aliquots at 
-20°C. 
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2.4 Biotinylation of PEI  
Both, PEI (MW = 25 kDa) and PEI600 (MW=600 Da) were biotinylated using a Sulfo-
NHS-LC-Biotin linker (Fig. 2.1) and kindly provided by Dr. Wenzhong Li (University of 
Rostock, Germany). Both types of biotinylated PEI were stored at amine concentrations of 7.5 
mM at 4°C. 
 
2.5 Filtration of MNP 
At first, Streptavidin MagneSphere® Paramagnetic Particles were sonicated for 15 min at 
room temperature (RT). In order to exclude aggregates and particles bigger than 450 nm, they 
were additionally filtered through a Millex-HV filter with a 0.45 µm pore size hydrophilic 
polyvinylidene difluoride (PVDF) membrane (Millipore, Tullagreen, Ireland) using a syringe. 
After filtration the iron concentration was measured as described below in section 2.5.1. The 
obtained suspension of MNP was stored in MNP buffer (PBS buffer containing 1mg/ml BSA), 
in aliquots at 4°C.  
2.5.1 Determination of iron concentration in filtered MNP 
For the determination of iron concentration, ultraviolet-visible (UV-VIS) 
spectrophotometry was used. The method was adopted from Rad et al., who reported that the 
described technique is sensitive and reproducible for determination of dissolved iron at a 
minimum concentration of 3µg/ml.  At first, the peak absorbance values for iron standard 
Figure 2.1: The principle of biotinylation of PEI using Sulfo-NHS-LC-Biotin linker. (Adapted from Thermo 
Fischer Scientific Inc., EZ-Link™ Sulfo-NHS-LC-Biotinylation Kit, Instructions, 2012) 
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(5µg/ml in water), blank solution (20µl MNP Buffer in 980 µl water) and MNP sample (20µl 
MNP in 980 µl water) were obtained (Fig.2.2a).  
 
 
Therefore, the samples in open glass tubes were incubated at 110°C overnight in order to 
evaporate the liquid. Afterwards, 1ml of hydrochloric acid (5 M) was added, tubes were capped 
and samples were further incubated at 60°C for 4 h. Following this incubation, the temperature 
of the samples was normalized to RT, samples were transferred to the 1.5 ml cuvettes and the 
absorbance profile of 200 – 500 nm wavelengths was obtained using a spectrophotometer. The 
peak absorbance value for the iron standard was 351 nm. The colored products are most likely 
to be obtained from the chemical reaction provided below: 
In the next step, the absorbance values of different iron standard dilutions (from 0 to 5 
µg/ml) at a wavelength of 351 nm were measured against blank solution in order to generate a 
calibration curve (Fig. 2.2b). The method showed a significant correlation between iron 
concentration and absorbance (R²> 0.99) and was further applied for the determination of the 
iron content in MNP samples.  
Fe
3
O
4
 + 8HCl 2FeCl
3
 + FeCl
2
 + 4H
2
O 
60°C, 4h 
Figure 2.2: Determination of iron concentration. Absorbance curves of blank solution (green), iron standard (red) 
and MNP sample (blue) (a); calibration curve for determination of iron concentration (b). 
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2.6 Preparation of transfection complexes  
2.6.1 pDNA/PEI and pDNA/PEI/MNP (MW(PEI) = 25 kDa) 
For preparation of both, pDNA/PEI and pDNA/PEI/MNP transfection complexes, pDNA 
and PEI solutions were first mixed at different molar ratios of PEI nitrogen to pDNA phosphate 
(NP ratios). pDNA and PEI were diluted in equal volumes of glucose solution in water (5%), 
well mixed and incubated for 30 min at RT. Plasmid DNA solution was always diluted to a 
concentration of 50 ng/µl. The required volumes of PEI solutions were calculated depending 
on NP ratio and required amount of pDNA, using the following equation:  
where:  
NP – NP ratio (refers to the number of nitrogen of PEI per pDNA phosphate); 
C(PEI) – concentration of amine nitrogen in PEI, mM; 
V(PEI) – volume of PEI to be used, µl; 
3 nmol of phosphate in 1 µg of pDNA; 
m(pDNA) – mass of pDNA to be used, µg. 
For preparation of pDNA/PEI/MNP complexes with final iron concentration from 0.5 to 6 
µg/ml, the appropriate amount of filtered MNP was added to pDNA/PEI complexes and 
incubated for 30 min at RT. pDNA/PEI and pDNA/PEI/MNP complexes were freshly prepared 
every time prior to transfection experiments. 
2.6.2 pDNA/PEI600 and pDNA/PEI600/MNP (MW(PEI) = 600 Da) 
Preparation of pDNA/PEI600 complexes was performed in a similar manner, as described 
above for pDNA/PEI. Plasmid DNA solution was always diluted to a concentration of 30 ng/µl 
for proper formation of pDNA/PEI600 complex.  
For the preparation of pDNA/PEI600/MNP transfection complexes, the required amount 
of MNP (from 2 to 16 µl) was added to pDNA/PEI600 mixture, well mixed and further 
incubated for 30 min at RT. In the part of work, referring to PEI600, Streptavidin 
MagneSphere® Paramagnetic Particles with an average effective hydrodynamic diameter of 
200 nm and iron content of 1 µg/µl (as to the information, provided by the supplier) were used 
without filtration.   
)(*3
)(*)(
pDNAm
PEIVPEIC
NP 
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2.7 Gel electrophoresis 
For gel electrophoresis, pDNA/PEI complexes (with pEGFP-N3 plasmid) at different NP 
ratios were prepared in the same way, as for transfection experiments (see Section 2.6). 10 µl 
of each sample were mixed with 2 µl of 6x Loading Dye and further loaded on 1% agarose gel, 
containing 6 µl of Ethidium Bromide, in TBE Buffer (Tris-borate-EDTA, pH=8.0) for 30 min 
at 120 v. GeneRuler™ 1 kb DNA Ladder was used as a reference. Afterwards the gel was 
analyzed using a ChemiDoc XRS System (BioRad Laboratories GmbH, Munich, Germany). 
2.8 Particle size and Zeta potential measurement  
The mean hydrodynamic diameter of both, filtered MNP and transfection complexes, was 
determined using Dynamic Light Scattering (DLS) technique with a Brookhaven 90Plus 
Nanoparticle Size Analyzer (Brookhaven Instruments, New York, NY). Surface charge was 
evaluated using Zeta Potential, which was measured by ZetaPALS Analyzer (Brookhaven 
Instruments) utilizing a Phase Analysis Light Scattering (PALS) method. For all 
measurements, transfection complexes were prepared in the same way, as described above (see 
Section 2.6). 
2.9 Transfection experiments  
2.9.1 Transfection with pDNA/PEI600 or pDNA/PEI600/MNP complexes 
(MW(PEI)=600 Da) 
For transfection experiments with PEI600, COS-7 cells (20 000 cells per well) were seeded 
in 48-well plates shortly before transfection. Afterwards, freshly prepared pDNA/PEI600 or 
pDNA/PEI600/MNP complexes (see Section 2.6.2) were added to the cells and gently mixed. 
The cell culture medium was replaced with the fresh one 48 h after transfection. Luciferase 
Reporter Gene Assays were performed after 72 h as described below (see Section 00).  
2.9.2 Transfection with pDNA/PEI or pDNA/PEI/MNP complexes (MW(PEI) = 25 
kDa) 
For transfection experiments with pDNA/PEI or pDNA/PEI/MNP complexes hMSC were 
seeded in different multiwell plates depending on the assay 24 h before transfection (Table 
2.1).  
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Assay Plate format Cell number/well 
Luciferase reporter gene assay 96-well plate 5 000 
EGFP expression assay  12-well plate 30 000 
Laser scanning microscopy 24-well plate 15 000 (on coverslips) 
 
At the day of transfection pDNA/PEI and pDNA/PEI/MNP complexes were prepared as 
described above (see Section 2.6.1) and added to the cells dropwise. Four hours after 
transfection hMSC were washed with PBS, medium was replaced with the fresh one, and cells 
were further incubated until the desired time point. 
2.10 Luciferase reporter gene assay  
For luciferase reporter gene assays, cells were transfected with pcDNA3.1-Luc plasmid, 
encoding firefly luciferase gene following the described protocol. For analysis cells were 
washed and lysed with Reporter Lysis Buffer at -80°C for 30 min. 10 µl of obtained cell lysate 
were mixed with Bright Glo Luciferase substrate (100 µl) and luminescence was immediately 
measured using Infinite 200 microplate reader (Tecan Trading AG, Maennedorf, Switzerland). 
Relative light units (RLU) were normalized against protein concentration determined by 
bicinchoninic acid (BCA) protein assay, which was performed in parallel.  
2.11 BCA protein assay 
For the determination of protein concentration BCA Protein Assay Kit was used. Briefly, 
25 µl of cell lysate were mixed with 200 µl of BCA Working solution according to the 
manufacturer’s protocol and incubated at 37°C for 30 min. Afterwards, the absorbance of the 
samples was measured at 550 nm wavelength by Bio-Rad Model 680 microplate reader (Bio 
Rad Laboratories GmbH, Munich, Germany). The protein concentration was finally calculated 
using a standard curve, which was prepared according the manufacturer’s protocol.   
2.12 EGFP expression assay 
For EGFP expression assays, cells were transfected with pEGFP-N3 plasmid as described 
above (see Sections 2.6 and 2.9). EGFP expression was at first observed under a fluorescent 
microscope Axiovert 40 CFL (Carl Zeiss, Goettingen, Germany). The images were acquired 
with ZEN 2010 Blue Software (Carl Zeiss, Jena, Germany). Afterwards cells were trypsinized, 
Table 2.1: Cell seeding numbers for Luciferase Reporter Gene Assay, EGFP expression assay and laser 
scanning microscopy. 
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washed with PBS and stained with DAPI for exclusion of dead cells. Subsequent quantitative 
analysis of transfection efficiency was performed using BD™ FACS LSR II flow cytometer 
(BD Biosciences, San Jose, CA). The data were acquired and analyzed using BD FACSDiva™ 
software (BD Biosciences).  
2.13  Determination of cell viability  
The viability of the cells was determined by measuring their metabolic activity using MTT 
reagent. For that cells were seeded in 96-well plate with 150 µl medium per well and transfected 
according to the described protocol (see Section 2.9). After 24 hours of incubation 15 µl of 
MTT solution (5 mg/ml in PBS) was added to the cells and further incubated for 4 hours at 
37˚C, 5% CO2. After spent medium was removed, purple formazan crystals were dissolved in 
100 µl DMSO. Optical density (OD) of the obtained solution was determined by Bio-Rad 
Model 680 microplate reader (Bio Rad Laboratories GmbH, Munich, Germany) at 550 nm 
wavelength with reference to 655 nm. Cell viability was calculated and normalized to control 
using the following formula: 
 
where:  
OD550 – optical density at 550 nm wavelength; 
OD655 – optical density at 655 nm wavelength. 
Cells treated with 5% glucose solution only (volume equal to transfection complexes) were 
used as control. 
2.14 Characterization of hMSC with and without transfection 
2.14.1 Immunophenotyping of hMSC  
Immunophenotyping of hMSC was performed 24 h after transfection with pcDNA3.1-Luc 
plasmid, performed by pDNA/PEI or pDNA/PEI/MNP complexes in 12-well plates as 
described above (see Section 2.9). For that cells were trypsinized and thoroughly washed with 
PBS. Afterwards tubes with cells were kept on ice and surface antigens of hMSC were labelled 
with the following anti-human conjugated antibodies: CD29-APC, CD44-PerCP-Cy5.5, 
CD45-V500, CD73-PE, CD117-PE-Cy7 and CD105-AlexaFluor 488. For that hMSCs were 
resuspended in MACS® buffer (EDTA (2mM)/BSA (0.5%) in PBS), counted and divided for 
Cell viability = 
(𝑂𝐷550−𝑂𝐷655)𝑠𝑎𝑚𝑝𝑙𝑒 
(𝑂𝐷550−𝑂𝐷655)𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
∗ 100% 
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following labelling. The required volume of antibodies was added and cells were incubated at 
4°C for 10 min. In the next step cells were gently washed with PBS and transferred to BD 
Falcon® 5 ml round-bottom tubes (BD Biosciences, San Jose, CA) for the following 
measurement. In order to determine unspecific binding and autofluorescence levels, mouse 
isotype antibodies were used as negative controls. Unstained cells served for the determination 
of cell population. Near-IR LIVE/DEAD® Fixable Dead Cell Stain Kit was used for the 
exclusion of dead cells in each sample according to the manufacturer’s protocol. Data were 
acquired using BD™ FACS LSR II flow cytometer and analyzed with BD FACSDiva™ 
software (BD Biosciences, San Jose, CA).  
2.14.2 Functional differentiation assay for hMSC  
Functional differentiation assay was performed using Human Mesenchymal Stem Cell 
Functional Identification Kit after transfection of hMSC with pDNA/PEI or pDNA/PEI/MNP 
complexes. For that cells were transfected with pcDNA3.1-Luc plasmid in 24-well plates on 
glass coverslips as described in Section 2.9.2 of the current chapter. Cells, which did not 
undergo transfection were used as a control. 24 h after transfection culture medium was 
replaced with αMEM Basal Medium, containing Adipogenic or Osteogenic Supplement in 
order to induce adipogenesis or osteogenesis, respectively. All required media supplements 
were included in the kit. The assay was performed following manufacturer’s protocol for 21 
days. Afterwards the specific markers for adipocytes and osteocytes (fatty acid binding protein-
4 (FABP-4) and osteocalcin respectively) were stained with Goat Anti-Mouse FABP4 and Goat 
Anti-Human Osteocalcin Antigen-affinity Purified Polyclonal Antibodies available from the 
kit. In order to perform further visualization of the cells, following fluorophore-conjugated 
secondary antibodies were used: Alexa Fluor 488 donkey anti-goat IgG and Alexa Fluor 488 
donkey anti-mouse IgG for FABP4 and osteocalcin staining, respectively. Cell nuclei were 
counterstained with DAPI and coverslips were mounted cell side down onto a drop of 
FluorSave™ Reagent on micrsocopic slides. Differentiation capacity was confirmed by 
confocal laser scanning microscopy (CLSM) using ELYRA PS.1 LSM 780 (Carl Zeiss, Jena, 
Germany) system and ZEN 2010D software (Carl Zeiss, Goettingen, Germany). 
2.15 Fluorescent labelling of transfection complexes 
The compounds of transfection complexes (pDNA, PEI and MNP) were separately labelled 
with different fluorophores as described below. The fluorescent dyes were carefully selected 
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according to their excitation and emission spectra in order to provide a maximum of intensity 
for each channel and avoid the overlap of detected signals (Fig. 2.3). 
 
pDNA (pcDNA3.1-Luc) was labelled with Cy™ 5 dye using Label IT® Tracker™ Intracellular 
Nucleic Acid Localization Kit according to the manufacturer’s protocol. Labelled pDNA was 
purified via ethanol precipitation in order to remove the unbound dye. The degree of labelling 
(DOL) was determined immediately after labelling according to the manufacturer’s protocol 
and was 5.35 pmol of dye per 1 µg of pDNA. Final pDNA-Cy5 solution was divided in aliquots 
and stored at -20°C, protected from light. 
For labelling of PEI with Oregon Green 488 (OG488) dye, the FluoReporter® Oregon 
Green® 488 Protein Labeling Kit was used. The whole procedure was performed according to 
the manufacturer’s protocol. At first, PEI solution was mixed with 1 M natrium bicarbonate 
solution. Afterwards, the reactive dye stock solution (10 mg/ml in DMSO) was added, and 
sample was continually mixed for 1 h (RT, protected from light). Purification of PEI-OG488 
solution was performed via centrifugation on a spin column available from the kit (1100 g, 5 
min). DOL was determined according to the manufacturer’s protocol, and was 0.037 moles of 
dye per 1 mol of PEI. PEI-OG488 solution was stored at 4°C in the dark. 
MNP were labelled with biotin-conjugated Atto 565 dye (A565) during the 
pDNA/PEI/MNP complex formation. For that, the required volume of A565 dye stock solution 
(200 ng/µl in DMSO) was directly added to pDNA/PEI complexes shortly after adding of MNP 
Figure 2.3: Set up for fluorescent labelling of transfection complexes. Labelled components (below) and 
corresponding dyes (up) with their excitation (dash lines) and emission spectra (bold lines). The colored areas 
roughly represent parts of spectra detected during the image acquisition. 
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(w/w ratio of A565 to MNP was 1 to 1000). Next, complexes were incubated for 30 min at RT 
according to the protocol of pDNA/PEI/MNP complex formation, described above. 
Effective diameter and surface charge of labelled transfection complexes were determined 
as described above (see section 2.8).  
2.16 Microscopy 
Super-resolution structured illumination microscopy, confocal microscopy and 
colocalization studies were performed using the LSM 780 ELYRA PS.1 system. 
The samples were prepared as follows: hMSC were seeded in 24-well plates on glass 
coverslips (0.13 – 0.16 mm thickness) and transfected with labelled transfection complexes as 
described in section 2.9. For all microscopic observations transfection was performed 
according to the optimized protocol conditions, that were NP ratio of 2.5, 3 µg/cm² pDNA (6 
µg pDNA per well) and 1 µg/ml of iron concentration within the pDNA/PEI/MNP complexes. 
At a required time point after transfection (2, 6, 12, 18, 24 or 48 hours) samples were 
thoroughly washed with 1M NaCl in order to remove transfection complexes which did not 
enter the cell and stayed at the cell surface. Next, cells were additionally washed with PBS and 
fixed with PFA (4% solution in PBS) for 20 min at RT.  Cell nuclei were stained with 250 nM 
DAPI solution. After final triple washing with PBS, coverslips were carefully mounted 
(avoiding additional pressure) with antifade reagent (FluorSave™ Reagent) on a microscopic 
slide.  
2.16.1 Superresolution structured illumination microscopy (SR-SIM) 
In order to visualize the labelled transfection complexes without a cell environment, 
pDNA-Cy5/PEI-OG488/MNP-A565 complexes were prepared as described above (see section 
2.15). Afterwards, a drop of freshly prepared complexes was added to the microscopic slide, 
dried out in the dark and covered with coverslip using a FluorSave™ Reagent. The samples 
were further observed using a 63x Plan Apochromat® objective (numerical aperture (NA) = 
1.4) with Immersol™ 518F immersion oil (Carl Zeiss, Oberkochen, Germany). For SR-SIM a 
special set of lasers and electron multiplying charge coupled device (EM-CCD) camera in a 
SIM mode of ZEN 2010D software were used. OG488, A565 and Cy5 were subsequently 
excited with 488 nm, 561 nm and 642 nm SIM - laser lines respectively. The number of SIM 
– grating rotations used for each image acquisition was maximum possible and reached 5. The 
CHAPTER 2. Materials and Methods 
 
  
 
33 
essential image processing was performed using a structured illumination module of the ZEN 
2010D software.   
2.16.2 Confocal laser scanning microscopy (CLSM) 
In this work, CLSM was employed for the following experiments: functional differentiation 
of hMSC, localization of transfection complexes, photobleaching experiments and 
colocalization studies. 
Table 2.2 contains the characteristics of fluorochromes, used in this work. It also includes 
description of laser lines, utilized for the excitation, and main beam splitters, which separated 
the emissions from the excitation light. Emission was recorded using photomultiplier detectors 
after careful adjustment of emission bands, avoiding spectral overlap. All images of multiple 
stainings were acquired in a channel mode. Thus the imaging parameters (gain and offset, the 
pinhole size, the filters and dichroics, the laser source) were defined for every track that served 
for the detection of one specific signal.  The tracks were scanned sequentially.  
 
 
Fluorochrom Exmax, nm Emmax, nm Laser line MBS 
DAPI 358 461 Diode 405 nm 405 
Oregon Green 488 501 526 Argon 458/488/514 nm 488/561/633 
Alexa Fluor 488 490 525 Argon 458/488/514 nm 488/561 
Atto 565 563 592 He/Ne 561 nm 488/561/633 
Cyan-5 649 666 He/Ne 633 nm 488/561/633 
 
To determine nuclear localisation of the transfection complexes, z-series images were 
acquired with 0.3 µm interval.  
In all experiments aiming to visualize transfection complexes, a 63x Plan Apochromat® oil 
immersion objective was used. In experiments of functional differentiation of hMSCs, a 40x 
Plan Neofluar (NA = 1.3) oil immersion and 20x Plan Apochromat® (NA = 0.8) dry objectives 
were used.  
Photobleaching experiments were performed using the bleaching tool of ZEN 2010D 
software at three selected regions of interest. Cy5, A565 and OG488 were bleached in 
independent experiments for 3 min with 633 nm, 561nm and 488 nm laser lines respectively, 
at high laser power. 
Table 2.2: List of fluorochromes and laser lines (incl. main beam splitters (MBS) used for their excitation.   
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2.16.3 Colocalization studies  
Prior to colocalization studies, in order to correct chromatic aberrations a channel alignment 
procedure was performed. For that, a MultiSpeck™ Multispectrual Fluorescence Microscopy 
Standard (Invirogen, Carlsbad, CA) was used. For colocalization studies the imaging 
parameters (gain, offset and laser power) were first adjusted using negative controls in order to 
subtract autofluorescence of the cells. After adjustment the settings were kept constant 
throughout all further experiments. Cells, transfected with unlabelled transfection complexes 
and further subjected to the same staining procedures as analysed samples were used as a 
negative control. In each sample 20 healthy looking hMSC were randomly selected and 
analysed for colocalization of Cy5 and OG488, Cy5 and A565, OG488 and A565 signals. For 
every analysed cell simultaneously with multichannel acquisition a transmission illumination 
image was obtained (using the laser light of one channel and transmission photomultiplier) in 
order to define the cell border, the background area and to adjust the threshold for every 
channel. Scatter diagrams of colocalization of pDNA-Cy5/PEI-OG488, pDNA-Cy5/MNP-
A565 and PEI-OG488/MNP-A565 signals were obtained at 2, 6, 12, 18 and 24 h after 
transfection. Manders’ colocalization coefficients (Ccoef) were calculated using colocalization 
module of ZEN 2010D software. These coefficients represent relative fluorescence of 
colocalized pixels as compared to the total fluorescence detected in one channel above 
threshold. Their values are independent of fluorescence intensity and demonstrate contribution 
of one channel to the colocalized pixels [148]. In this study the Ccoef  were calculated according 
to the formulas below.  
To determine how many pDNA-Cy5 pixels were colocalized with PEI-OG488 pixels:  
 
C𝑐𝑜𝑒𝑓(pDNA to PEI) =
∑ (𝑝𝐷𝑁𝐴)𝑝𝑖𝑥𝑒𝑙𝑠, 𝑐𝑜𝑙𝑜𝑐 𝑤𝑖𝑡ℎ 𝑃𝐸𝐼𝑖
∑ (𝑝𝐷𝑁𝐴)𝑝𝑖𝑥𝑒𝑙𝑠, 𝑡𝑜𝑡𝑎𝑙𝑖
 
 
To determine how many PEI-OG488 pixels were colocalized with MNP-A565 pixels: 
 
C𝑐𝑜𝑒𝑓(PEI to MNP) =
∑ (𝑃𝐸𝐼)𝑝𝑖𝑥𝑒𝑙𝑠, 𝑐𝑜𝑙𝑜𝑐 𝑤𝑖𝑡ℎ 𝑀𝑁𝑃𝑖
∑ (𝑃𝐸𝐼)𝑝𝑖𝑥𝑒𝑙𝑠, 𝑡𝑜𝑡𝑎𝑙𝑖
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To determine how many pDNA-Cy5 pixels were colocalized with MNP-A565: 
 
C𝑐𝑜𝑒𝑓(pDNA to MNP) =
∑ (𝑝𝐷𝑁𝐴)𝑝𝑖𝑥𝑒𝑙𝑠, 𝑐𝑜𝑙𝑜𝑐 𝑤𝑖𝑡ℎ 𝑀𝑁𝑃𝑖
∑ (𝑝𝐷𝑁𝐴)𝑝𝑖𝑥𝑒𝑙𝑠, 𝑡𝑜𝑡𝑎𝑙𝑖
 
. 
2.17 Statistical analysis 
Mann-Whitney test was used for analysis of differences in EGFP expression of hMSC from 
different patients. Statistical analysis in all other experiments was performed using Student’s 
t-test. Particle size values are presented as mean ± standard deviation (SD). All other values 
are presented as mean ± standard error of the mean (SEM). Values with p ≤ 0.05 were 
considered to be significantly different. 
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3 Results 
3.1 Transfection in hMSC 
3.1.1 Characterization of transfection complexes (MW(PEI) = 25 kDa) 
In order to confirm the formation of pDNA/PEI complexes at low NP ratios we have 
analysed them by gel electrophoresis (Fig. 3.1). At NP ratios of 0.25, 0.5 and 0.75 the pDNA 
band was clearly visible and did not differ from the sample with pDNA alone. At NP ratio of 
1 the band was hardly detectable and disappeared completely at NP 1.5, indicating complete 
retardation of pDNA by pDNA/PEI complexes. 
According to the results obtained previously for COS-7 cells, the optimal NP ratio for 
effective transfection was 2.5 [149, 150]. Therefore, transfection complexes at NP ratio of 2.5 
were further characterized by effective diameter and surface charge in this work. For that MNP 
alone, pDNA/PEI and pDNA/PEI/MNP (1 µg/ml iron) complexes were analyzed by DLS and 
PALS (Table 3.1). The effective diameter of MNP alone was 168.6 ± 10.25 nm. The surface 
charge of MNP alone was negative (-29.17 ± 0.98 mV). pDNA/PEI and pDNA/PEI/MNP 
complexes were positively charged (+21.6 ± 2.41 mV and +26.8 ± 1.56 mV, respectively). Size 
distributions were 78.39 ± 3.07 nm for pDNA/PEI complexes and from 112.1 ± 6.84 nm for 
pDNA/PEI/MNP.  
 
Figure 3.1: Gel electrophoresis of pDNA/PEI transfection 
complexes at different NP ratios (from 0.25 to 3.0) in 
comparison to pDNA alone. 
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 Particle size, nm Zeta potential, mV 
MNP 168.6 ± 10.25 -29.17 ± 0.98 
pDNA/PEI 78.39 ± 3.07 +21.6 ± 2.41  
pDNA/PEI/MNP 112.1 ± 6.84 +26.8 ±1.56  
 
3.1.2 Optimization of transfection conditions with pDNA/PEI/MNP complexes 
(MW(PEI) = 25 kDa) in hMSC 
For the optimization of transfection conditions in hMSC different pDNA amounts (from 1 
to 6 µg/cm2) were tested (Fig. 3.2a). A significant difference in reporter gene expression 
between pDNA/PEI- and pDNA/PEI/MNP-mediated transfection was first observed at a 
pDNA concentration of 3 µg/cm2. Transfection efficiency with magnetic polyplexes was higher 
than those of polyplexes. Although transfection rates raised further with the increase of pDNA 
dosage, cell viability decreased (Fig. 3.2b). Therefore, 3 µg/cm2 of pDNA, NP ratio 2.5 and 1 
µg/ml of iron content were considered to be the optimal conditions for hMSC transfection with 
pDNA/PEI/MNP complexes.  This composition was used in all further experiments.  
3.1.3 pEGFP transfection 
Transfection with pEGFP was performed in order to confirm the above obtained data (Figs. 
3.2 c, d). The diagram in Figure 3.2c represents results of FACS analyses of pEGFP-transfected 
cells. Magnetic polyplexes were able to reach up to 22% of transfection efficiency in living 
cells, whereas 3% of living cells were positive after pDNA/PEI-mediated transfection. 
Transfection efficiency in cells from different patients varied dramatically, however mean 
values between the carriers were still different: 1.6% for pDNA/PEI vs. 9.7% for 
pDNA/PEI/MNP.  The representative fluorescence microscopy images of pDNA/PEI and 
pDNA/PEI/MNP-mediated transfection are shown in Figure 3.2d, confirming the better 
performance of magnetic polyplexes.  
Table 3.1 Particle size and surface charge of magnetic nanoparticles alone and transfection complexes (NP 
ratio 2.5, 1 µg/ml iron) determined by DLS and PALS, respectively. Data represent the mean ± SD (n=10) [149].   
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3.1.4 Characterization of hMSC 
Characterization of bone marrow hMSC was initially performed at passage 3 after the 
isolation procedure. For that, cell morphology, as well as differentiation capacity and surface 
marker expression were checked. At passage 3 hMSC had a typical spindle shape and 
maintained their morphology during subsequent passages. Flow cytometry analysis revealed 
Figure 3.2: Optimization of transfection conditions with pDNA/PEI/MNP complexes in comparison to pDNA/PEI 
complexes (MW(PEI) = 25 kDa) in hMSC. (a,b) Transfection complexes were prepared with varied pDNA amounts 
(from 1 to 6 µg/cm²), while other parameters were kept constant (NP ratio 2.5 and 1 µg/ml of iron). The cells were 
transfected according to the protocol. 24 h after transfection, a luciferase reporter gene assay and MTT – assay 
were performed in order to evaluate transfection efficiency (a) and cell viability (b) respectively. Results are 
representative of 3 independent experiments, each involved 8 replicates (n=8). The values are shown as mean ± 
SEM. Asterisks represent a significant difference in transfection efficiency (*p ≤ 0.05) as compared to pDNA/PEI 
complexes. (c) Transfection efficiency of magnetic polyplexes in comparison to polyplexes (3 µg/cm2 of pDNA, NP 
ratio 2.5, 1 µg/ml of iron) was assessed in hMSC isolated from different patients by flow cytometry 24 h after 
transfection with pEGFP. The average number of EGFP – expressing  cells detected after pDNA/PEI or 
pDNA/PEI/MNP transfection, relative to the whole cell population was plotted (n=5). The bars represent the mean 
values. Asterisks represent a significant difference, as determined by Mann-Whitney test (**p ≤ 0.01). (d) 
Representative fluorescence microscopy images of EGFP expressing hMSC 24 h after transfection with pDNA/PEI 
or pDNA/PEI/MNP complexes (3 µg/cm2 of pDNA, NP ratio 2.5, 1 µg/ml of iron). Scale bars = 10 µm. Adapted 
from [149]. 
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that cells expressed surface markers, typical for mesenchymal stem cell populations: CD29, 
CD44, CD73 and CD105, and were negative for hematopoietic surface markers: CD45 and 
CD117 (Table 3.2).  
 
Differentiation capacity analysis demonstrated that derived hMSC did differentiate into 
adipocytes and osteocytes when cultured in adipogenic and osteogenic media, respectively 
(Fig. 3.3a, d).  
 Surface marker, % 
 CD 29 CD 44 CD 45 CD 73 CD 105 CD 117 
No transfection 99.8 ± 0.1 99.8 ± 0.1 0.0 ± 0.0 99.6 ± 0.1 98.4 ± 0.5 0.0 ± 0.0 
pDNA/PEI 99.5 ± 0.2 99.7 ± 0.1 0.0 ± 0.0 97.4 ± 1.9 97.4 ± 0.4 0.0 ± 0.0 
pDNA/PEI/MNP 98.9 ± 0.5 99.6 ± 0.2 0.0 ± 0.0 99.3 ± 0.2 96.7 ± 0.4 0.0 ± 0.0 
Figure 3.3: Characterization of hMSC. Differentiation capacity towards adipocytes and osteocytes without 
transfection (a, d) and after transfection with pDNA/PEI (b, e) or pDNA/PEI/MNP (c, f) complexes (3 µg/cm2 of 
pDNA, NP ratio 2.5, 1 µg/ml of iron). The assay was started 24 h after transfection and was analysed after 21 days 
by immunohistochemistry. Scale bars = 50 µm. Adapted from [149]. 
Table 3.2 Characterization of hMSC. Expression of typical surface markers was evaluated by flow cytometry 
before and 24 h after transfection with pDNA/PEI or pDNA/PEI/MNP complexes (3 µg/cm2 of pDNA, NP=2.5, 1 
µg/ml iron). Data represent the mean ± SD (n=3) [149].  
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Similar characterization of hMSC was performed after their transfection with pDNA/PEI 
or pDNA/PEI/MNP complexes with the aim to check the well-being of the cells (Fig. 
3.3b,c,e,f). Cell morphology did not change compared to untransfected cells. The analysis of 
immunophenotype after transfection with either polyplexes or magnetic polyplexes did not 
reveal any significant changes in expression of characteristic hMSC surface markers (Table 
3.2). Furthermore transfected hMSC were able to differentiate into adipocytes and osteocytes 
in the same manner as untransfected cells (Fig. 3.3).  
3.1.5 Monitoring of transfection efficiency in hMSC over time 
Transfection efficiency in hMSC was monitored at 2, 6, 12, 18, 24 and 48 h time points 
after transfection with pDNA/PEI or pDNA/PEI/MNP complexes. In these experiments a 
luciferase reporter gene assay was used. The data are presented in Figure 3.4. The level of 
reporter gene expression remarkably increased already at the 12 h time point and raised slightly 
over time for both, polyplexes- and magnetic polyplexes-mediated transfection.  
 
A maximum of transfection efficiency was observed 24 h after transfection in both cases. 
Reporter gene expression levels in hMSC after pDNA/PEI/MNP-mediated transfection were 
significantly higher than those after pDNA/PEI – mediated transfection at 12, 18, 24 and 48 h 
time points after transfection (Fig. 3.4).  
Figure 3.4: Monitoring of transfection efficiency in 
hMSC over time. Transfection efficiency at 
different time points (from 2 to 48 h) was evaluated 
by luciferase reporter gene assay after 
transfection with pNDA/PEI or pDNA/PEI/MNP 
complexes (3 µg/cm2 of pDNA, NP ratio 2.5, 1 
µg/ml of iron). Results are representative of 3 
independent experiments, each involved 8 
replicates (n=8). The values are shown as mean ± 
SEM. Asterisks represent a significant difference 
in transfection efficiency (*p ≤ 0.005) as compared 
to pDNA/PEI complexes at each time point. 
Adapted from [149]. 
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3.2 Mechanism of MNP-mediated transfection 
3.2.1 Characterization and visualization of fluorescently labelled transfection 
complexes 
Fluorescently labelled transfection complexes were previously optimized and characterized 
by our group regarding their transfection efficiency and cytotoxicity in the COS-7 cell line. 
These data were described elsewhere [149, 150].  
In this study luciferase reporter gene assays after transfection with three-color labelled 
complexes (pDNA-Cy5/PEI-OG488/MNP-A565) or single-labelled complexes were 
performed in hMSC (Fig. 3.5a). Importantly, no significant differences in transfection 
efficiency in comparison to unlabelled pDNA/PEI/MNP complexes were observed. Moreover, 
no influence of fluorescent labelling on cytotoxicity of transfection complexes was detected in 
all four compositions (Fig 3.5a).  
 
Figure 3.5: Characterization and visualization of 
fluorescently labelled transfection complexes. (a) 
Influence of single-labelling or three-color 
labelling of magnetic polyplexes on transfection 
efficiency (luciferase reporter gene assay) and 
cell viability (MTT - assay) was evaluated in 
hMSC 24 h after transfection (3 µg/cm2 of pDNA, 
NP ratio 2.5, 1 µg/ml of iron).  Results are 
representative of 3 independent experiments, 
each involved 8 replicates (n=8). Data are shown 
as mean ± SEM. No significant differences in 
transfection efficiency and cell viability were 
detected compared with unlabelled complexes. 
(b) SIM – microscopy images (single channels 
and merged) of three-color labelled magnetic 
transfection complexes in the absence of cells. 
pDNA was labelled with Cy5 dye (cyan), MNP 
were labelled with A565 dye (red),  PEI was 
labelled with OG488 dye (blue). Scale bars = 0.5 
µm. Adapted from [149]. 
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Figure 3.5b shows a SIM-image of labelled pDNA/PEI/MNP complexes in the absence of 
cells. The complexes had a spherical shape, their size ranged from 300 to 500 nm. Signal 
intensities in all three channels provided appropriate signal-to-noise ratio. According to the 
acquisition, pDNA, PEI and MNP were visually colocalized.   
 
Particle size and surface charge of labelled magnetic polyplexes were determined using 
DLS and PALS techniques. The parameters for single-labelled and three-color labelled 
complexes were obtained and compared with each other (Table 3.3). Transfection complexes 
with single labelling of pDNA, as well as complexes with single labelling of MNP did not 
differ in size and surface charge from unlabelled complexes. Single labelling of PEI led to a 
slight increase in effective diameter and slight decrease in Zeta potential of magnetic 
polyplexes, as compared to unlabelled ones. The same effect was observed for three-color 
labelled transfection complexes. Therefore, an effective diameter of pDNA-Cy5/PEI-
OG488/MNP-A565 complexes was between 207.73 and 231.35 nm, the surface charge was 
+22.79 ± 0.76 mV.  
 Particle size, nm Zeta potential,  mV 
pDNA-Cy5/PEI/MNP 116.27 ± 10.48 +27.39 ± 2.48 
pDNA/PEI-OG488/MNP 208.2 ± 19.65 +17.56 ± 3.66  
pDNA/PEI/MNP-A565 118.17 ± 5.15 +29.0 ± 2.59  
pDNA-Cy5/PEI-OG488/MNP-A565 219.54 ± 11.81 +22.79 ± 0.76 
 
The photobleaching experiments were previously performed by our group and are 
described in detail elsewhere [149, 150]. These results are summarized in Figure 3.6. In the 
course of bleaching with 633 nm laser, an intensity of Cy5 reduced significantly until the signal 
was not detectable anymore, whereas intensities of A565 and OG488 signals remained 
unchanged (Fig. 3.6a, d). Photobleaching with 561 nm laser at high power led to a decrease in 
fluorescence intensity of A565, while no increase in fluorescence intensities of OG488 and 
Cy5 occurred (Fig. 3.6b). In a similar manner, photobleaching with 488 nm laser line caused a 
time-dependent decrease in signal intensity of OG488 and no intensity changes of A565 and 
Cy5 (Fig. 3.6c).   
Table 3.3. Particle size and surface charge of single-labelled and three-color labelled magnetic transfection 
complexes (NP ratio 2.5, 1 µg/ml iron) determined by DLS and PALS, respectively. Data represent the mean ± 
SD (n=10) [149]. 
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3.2.2 Intracellular localization of transfection complexes 24 h after transfection 
Intracellular localization of transfection complexes was observed by CLSM of transfected 
hMSC. For that a z-series of images were acquired and analysed (Fig. 3.7 and 3.8). 
At a 24 h time point after pDNA/PEI-mediated transfection, both, pDNA and PEI signals 
(visually colocalized) were found in the nuclei of hMSC (Figs. 3.7a and 3.8 b, b´). On the 
contrary, 24 h after pDNA/PEI/MNP-mediated transfection, no events were observed directly 
in the cell nuclei (Figs. 3.7b and 3.8 a, a´). 
A thorough z-stack analysis discovered three well distinguishable types of events in the 
perinuclear/nuclear region of hMSC (Fig. 3.8a´´): condensed pDNA/PEI/MNP complexes (1); 
groups of PEI-OG488 signals visually colocalized with MNP-565 signals and surrounded by 
Figure 3.6: Photobleaching experiments. Three-color labelled magnetic transfection complexes (NP ratio 2.5, 1 
µg/ml iron) in the absence of cells were fixed on microscopic slides and visualized by laser scanning microscopy. 
pDNA was labelled with Cy5 dye (cyan), MNP were labelled with A565 dye (red), PEI was labelled with OG488 
dye (blue). The fluorophores Cy5, A565 and OG488 were bleached in independent experiments for 3 min with 633 
nm (a,d), 561nm (b) and 488 nm (c) laser lines respectively, at high laser power. The plots represent changes in 
fluorescent intensities over time. (d) Representative image of Cy5 photobleaching experiment. Scale bar = 1 µm. 
Adapted from [149, 150]. 
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diffused signal of DNA-Cy5 colocalized with DAPI (2); single DNA-Cy5 signals inside the 
nucleus (3). 
 
  
Figure 3.7: Intracellular localization of transfection complexes in hMSC 24 h after transfection. hMSC were 
transfected with fluorescently labelled pDNA/PEI or pDNA/PEI/MNP complexes (3 µg/cm2 of pDNA, NP ratio 2.5, 
1 µg/ml of iron) and visualized by CLSM 24 h after transfection. pDNA was labelled with Cy5 dye (cyan), MNP were 
labelled with A565 dye (red),  PEI was labelled with OG488 dye (blue), nuclei were stained with DAPI (orange). 
Merged and single channel – confocal microscopy images of cells transfected with pDNA/PEI (a) or pDNA/PEI/MNP 
(b) complexes. Red arrows indicate intranuclear localization of pDNA/PEI complexes. White arrows indicate 
possible pDNA release event in the perinuclear region. Scale bars = 5µm. Taken from [149]. 
CHAPTER 3. Results 
 
  
 
45 
 
Figure 3.8: Intracellular localization of transfection complexes in hMSC 24 h after transfection, including possible 
pDNA release events. hMSC were transfected with fluorescently labelled pDNA/PEI or pDNA/PEI/MNP 
complexes (3 µg/cm2 of pDNA, NP ratio 2.5, 1 µg/ml of iron) and visualized by CLSM 24 h after transfection. 
pDNA was labelled with Cy5 dye (cyan), MNP were labelled with A565 dye (red),  PEI was labelled with OG488 
dye (blue), nuclei were stained with DAPI (orange). Representative z-series of hMSC 24 h after transfection with 
pDNA/PEI/MNP (a) or pDNA/PEI (b) complexes. Magnified images of 0.6 µm – optical sections of cells transfected 
with pDNA/PEI/MNP (a’) or pDNA/PEI (b’). Red arrows indicate intranuclear localization of polyplexes. (a’’) 
Magnified area of interest and single channel images show three events, possibly related to pDNA release 
process: (1) condensed pDNA/PEI/MNP complexes, (2) release of pDNA, (3) nuclear localization of pDNA. Scale 
bars = 2 µm. Adapted from [149]. 
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3.2.3 Monitoring of pDNA release from transfection complexes in hMSC 
Monitoring of pDNA release from transfection complexes was performed using 
colocalization studies in hMSC, transfected with labelled pDNA/PEI or pDNA/PEI/MNP 
complexes. Figures 3.9c and d show representative scatter diagrams, obtained in the course of 
colocalization studies to calculate Ccoef. Thus, Figure 3.9c demonstrates the changes in 
colocalization of pDNA and PEI signals within pDNA/PEI or pDNA/PEI/MNP complexes 
with the time (at 2, 12 and 24 h time points).  
Obviously, the population of colocalized pixels in both cases reduces in size, as signals 
start to spread along the axes. However, this process is more evident in magnetic polyplexes, 
than in pDNA/PEI complexes. Figure 3.9d represents colocalization diagrams of PEI and MNP 
signals within the pDNA/PEI/MNP complexes. Here, the population of colocalized pixels did 
not change significantly over time. The results of detailed colocalization analysis at 2, 6, 12, 
18 and 24 h after transfection are shown in Figures 3.9a and b. Ccoef for pDNA-Cy5 and PEI-
OG488 in samples with pDNA/PEI - or pDNA/PEI/MNP – transfected cells are presented in 
Figure 3.9a. At 2 h time point significantly more pDNA-Cy5 signals were colocalized with 
PEI-OG488 signals in magnetic polyplexes compared to pDNA/PEI complexes. Over time, in 
both cases Ccoef decreased, signalizing a loss of pDNA within transfection complexes. 
However, at later time points pDNA-PEI colocalization values in pDNA/PEI/MNP – 
transfected hMSC were significantly lower, than those in pDNA/PEI – transfected cells. 
Furthermore, 6 h after transfection a significant decrease of pDNA, colocalized with PEI, was 
observed in the case of magnetic polyplexes. All in all the mean value of Ccoef  dropped from 
0.91 to 0.38 in 24 h (58.3% loss), whereas Ccoef for pDNA within pDNA/PEI complexes 
reduced its mean value from 0.82 to 0.60 in the same timeframe (26.8% of loss). Additionally 
we analyzed the loss of pDNA in magnetic polyplexes in relation to MNP-A565 signal (Ccoef 
of pDNA to MNP).These data are shown in Figure 3.9b.  
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Figure 3.9: Monitoring of pDNA release from transfection complexes in hMSC. hMSC were transfected with 
fluorescently labelled pDNA/PEI or pDNA/PEI/MNP complexes (3 µg/cm2 of pDNA, NP ratio 2.5, 1 µg/ml of iron), 
visualized by CLSM at different time points after transfection (2, 6, 12, 18, 24 h) and analysed for colocalization of 
Cy5 and OG488, Cy5 and A565, OG488 and A565 signals. Cells, transfected with unlabelled complexes were used 
as a negative control. pDNA was labelled with Cy5 dye (cyan), MNP were labelled with A565 dye (red),  PEI was 
labelled with OG488 dye (blue), nuclei were stained with DAPI (orange). (a) Changing of Ccoef of pDNA and PEI 
signals over time in hMSC, transfected with pDNA/PEI or pDNA/PEI/MNP complexes. (b) Ccoef of PEI and MNP 
signals in comparison with Ccoef of pDNA and MNP signals over time in hMSC, transfected with pDNA/PEI/MNP 
complexes. Data are shown as mean ± SEM (n = 20). Representative scatter diagrams of colocalization 
experiments for (c) pDNA and PEI signals or (d) PEI and MNP signals in transfected hMSC at different time points. 
Red numbers indicate the values of (c) Ccoef (pDNA to PEI) and (d) Ccoef (PEI to MNP). Adapted from [149]. 
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The changes in Ccoef had a similar dynamic as colocalization of pDNA to PEI within 
pDNA/PEI/MNP complexes. The mean value dropped from 0.95 to 0.45 (47.4 % loss). 
Moreover, in a similar manner we investigated the colocalization behavior of MNP-A565 and 
PEI-OG488 signals over time (Fig. 3.9b). At the first time point (2 h) both signals were strongly 
colocalized. Over time the mean values of Ccoef  did not change significantly.  
3.3 Transfection with LMW PEI-based magnetic complexes 
(MW(PEI)= 600 Da) 
3.3.1 Characterization of pDNA/PEI600 transfection complexes 
pDNA/PEI600 complexes were characterized by effective diameter and surface charge 
using the same techniques as for transfection complexes with high-molecular weight PEI. The 
results are presented in Figure 3.10. Detected by DLS, the effective diameter was maximal at 
NP ratio of 5 and significantly decreased at higher NP ratios. The size of complexes with NP 
ratios of 40 – 140 remained in range from 160 to 230 nm (Fig. 3.10a).  
 
Zeta potential data, obtained by PALS, confirmed the correlation between NP ratio and 
effective diameter of transfection complexes, described above. pDNA alone had a negative 
surface charge (-20 mV) that turned to positive when PEI 600 was added at NP ratio of 20. At 
NP ratios of 40 – 140 the Zeta potential ranged from +9 mV to +15 mV, indicating the balance 
between positively charged PEI600 and negatively charged pDNA (Fig. 3.10b). 
Figure 3.10: Characterization of pDNA/PEI600 transfection complexes. Particle size (a) and surface charge (b) of 
pDNA/PEI600 transfection complexes prepared at different NP ratios (from 20 to 140) were determined by DLS 
and PALS, respectively. Data represent the mean ± SEM (n=10). Adapted from [151]. 
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3.3.2 Optimization of transfection conditions with pDNA/PEI600/MNP complexes 
in COS-7 cell line 
For the optimization of transfection conditions with pDNA/PEI600/MNP complexes (NP 
ratio, MNP amount), luciferase reporter gene assays and MTT cytotoxicity assays were used 
(Fig. 3.11). Figure 3.11a demonstrates transfection efficiencies of pDNA/PEI600 complexes at 
NP ratios of 40 – 140. The highest value of reporter gene expression was observed at NP ratio 
of 100 (1.6*105 RLU/mg of protein). Therefore it has been chosen for further optimization of 
MNP amounts, which is shown in Figure 3.11b.  
Interestingly, transfection efficiency increased significantly (4-fold) compared with 
pDNA/PEI600 complexes even when small amounts of MNP were used (2 µg of iron per well). 
Figure 3.11: Optimization of transfection conditions with PEI600-containing complexes in COS-7 cells. The cells 
were transfected with (a) pDNA/PEI600 complexes (NP ratios from 40 to 140, 3 µg pDNA/well) or with (b) 
pDNA/PEI600/MNP complexes (NP ratio 100, 3 µg pDNA/well, 0 – 14 µg of MNP per well). 72 h after transfection, 
a luciferase reporter gene assay was performed in order to evaluate transfection efficiency. Results are 
representative of 3 independent experiments, each involved 8 replicates (n=8). The values are shown as mean ± 
SEM. Asterisks represent a significant difference in transfection efficiencies (*p ≤ 0.05, **p ≤ 0.005, #p ≤ 0.0005) 
as compared to pDNA/PEI600 complexes at NP ratio 100. (c) Representative fluorescence microscopy images 
(single channels and merged) of EGFP expressing COS-7 cells 72 h after transfection with pDNA/PEI600/MNP 
complexes (3 µg pDNA/well, NP ratio 100, 10 µg MNP per well). Scale bars = 50 µm. 
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However, the highest gene expression level was detected when 10 µg of MNP per well were 
used. In the latter case, 9-10 fold enhancement was observed, and reporter gene expression 
reached 2.7*106 RLU/mg of protein. Nevertheless, higher amounts of MNP led to a significant 
decrease in transfection efficiency. All in all the transfection rates of pDNA/PEI600/MNP 
complexes were lower than those of pDNA/PEI (MW(PEI) = 25 kDa) complexes. Thus, NP ratio 
of 100 and 10 mg of MNP per well were selected as optimal conditions for 
pDNA/PEI600/MNP transfection. 
Afterwards cytotoxicity of PEI600-mediated transfection was checked via MTT - assay and 
compared with pDNA/PEI (MW(PEI) = 25 kDa) transfection (Fig. 3.12). Both, pDNA/PEI600 
and pDNA/PEI600/MNP complexes showed more than 80% of cell viability after transfection. 
Moreover, in both cases cytotoxicity was lower than after pDNA/PEI (MW(PEI) = 25 kDa)-
mediated transfection [151].  
 
In order to confirm the obtained data, a representative pEGFP transfection with 
pDNA/PEI600/MNP complexes at NP ratio of 100 and 10 µg of MNP per well is shown in 
Figure 3.11c.  
Figure 3.12: Cytotoxicity of PEI600-mediated 
transfection. COS-7 cells were transfected with 
pDNA/PEI600 (3 µg pDNA/well, NP ratio 100) or 
pDNA/PEI600/MNP (3 µg pDNA/well, NP ratio 100, 10 
µg MNP per well) complexes. 48 h after transfection, 
MTT – assay was performed in order to evaluate the 
cell viability. The data were compared with 
DNA/PEI/MNP (MW(PEI) = 25 kDa, 3 µg pDNA/well, NP 
ratio 5)-mediated transfection. Results are 
representative of 3 independent experiments, each 
involved 8 replicates (n=8). The values are shown as 
mean ± SEM. Adapted from [151]. 
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4 Discussion  
Initially, the MNP-based gene delivery system, studied in this work, was introduced by our 
group in 2008 [144]. As pilot in vitro and in vivo studies had been very promising, subsequent 
optimization of the carrier was performed by Anna Schade later on [149, 150]. The results 
showed that at certain conditions magnetic polyplexes were 100 – 1000 fold more efficient 
than pDNA/PEI complexes even without application of magnetic field. As a result of thorough 
optimization experiments in COS-7 we developed a transfection strategy, where low NP ratio, 
low MNP amount and optimal pDNA quantity may be of use for genetic modifications of 
“difficult-to-transfect” cells (i.e. stem cells) [150]. It is commonly known that such cell types 
are usually available in low amounts and are very sensitive to any toxic agents and procedures. 
Therefore, they strongly require a non-toxic and efficient approach for gene delivery. 
Recent advances in stem cell research have brought new light to the use of stem cells for 
regenerative medicine and tissue engineering. Due to self – renewal and differentiation 
capacity, stem cells are of great interest for cell transplantation therapies, including 
regenerative medicine, cancer therapy and gene therapy. Genetic modifications of both, 
embryonic and adult stem cells could be performed to promote their differentiation ex vivo or 
to enhance their survival, selectivity and therapeutic effect in vivo [152].  
One of the most promising and investigated adult stem cell types are hMSC. They have 
been discovered in various tissues and are often isolated from bone marrow. As these cells are 
widely used in biomedicine, The International Society for Cellular Therapy in 2006 proposed 
the minimal criteria to define hMSC. They include obligatory plastic adherence, expression of 
certain surface markers (CD105, CD73, CD29 and CD90), lack of expression of CD11b, CD14, 
CD19, CD34, CD45, CD79α, CD117, HLA-antigen D-related. Moreover, the cells must be 
able to differentiate into adipocytes, osteocytes and chondrocytes under specific culture 
conditions [153]. Transplantation of hMSC was already shown to support cardiac regeneration, 
as these cells express matrix-mediating, antiapoptotic and angiogenic factors [154]. Moreover, 
their genetic modification before transplantation can improve cell survival and regenerative 
capacity, thus facilitating the recovery of infarcted tissue [155, 156].   
Due to low toxicity and high efficiency, the transfection strategy described by our group 
previously [144, 150] could serve as a mild approach for genetic modifications of hMSC in 
vitro. Magnetic properties of pDNA/PEI/MNP complexes might allow subsequent in vivo 
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monitoring of modified cells after their transplantation by MRI, as well as selective targeting 
to the desired tissue by an external magnetic field. 
4.1 Transfection in hMSC 
4.1.1 Characterization of transfection complexes (MW(PEI) = 25 kDa) 
Characterization of pDNA/PEI and pDNA/PEI/MNP transfection complexes by PALS 
revealed that both systems have a well detectable positive surface charge exceeding +20 mV 
(Table 3.1). This confirms the stability of the complexes and their potential for successful 
interaction with negatively charged cell membrane. The DLS demonstrated that the 
hydrodynamic diameters of both systems were below 120 nm, though magnetic polyplexes 
were slightly bigger than polyplexes. Interestingly, the detected effective diameter of MNP 
alone was bigger than those of transfection complexes, probably due to tight binding of 
pDNA/PEI complexes on the surface of MNP via biotin – streptavidine linker. This fact may 
provide evidence, that transfection systems possess better colloidal properties and spherical 
stability than pure MNP.  
Condensation assays for NP ratios ranging from 0.5 to 5 demonstrated that pDNA in 
polyplexes was completely retarded by PEI already at NP ratio 1.5 (Fig. 3.1). 
4.1.2 Optimization of transfection in hMSC 
The extensive optimization experiments in the COS-7 cell line, described previously [149, 
150], provided reproducible and reliable data. This allowed the direct application of the 
optimized parameters for transfection in hMSC, thus saving human patient material for other 
experiments. However, the transfection rates with 1 µg/cm2 of pDNA were not high enough, 
therefore the pDNA amount was increased (Fig. 3.2a), that let to a significant decrease in cell 
viability (Fig. 3.2b). Another difficulty regarding hMSC transfection was a remarkably varying 
transfection efficiency among cells from different patients. This fact corresponds to previous 
findings of our group [157]. Nonetheless, magnetic polyplexes performed always better than 
polyplexes, demonstrating higher transfection rates even in the absence of a magnetic field 
(Fig. 3.2a, c, d). Thus, the mean transfection efficiency of pDNA/PEI/MNP was about 10%, 
while pDNA/PEI reached only 1.6% (Fig. 3.2c).  
According to the International Society for Cellular Therapy, hMSC are characterized by 
the expression of specific surface markers and multilineage differentiation [153]. Therefore, it 
is of importance for future clinical applications, to maintain these characteristics after genetic 
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modifications. Therefore, in this work, immunophenotyping and differentiation assays were 
performed before and after transfection. Neither pDNA/PEI, nor magnetic polyplexes 
demonstrated any influence on surface markers expression (Table 3.2) and differentiation 
capacity (Fig. 3.3) of hMSC. These important results indicate the relative safety of both 
transfection methods.  
4.1.3 Monitoring of transfection overtime 
In order to better understand the transfection process, reporter gene expression in hMSC 
was monitored overtime for 48 h after transfection with either pDNA/PEI or pDNA/PEI/MNP 
complexes. Low levels of luciferase expression were observed as early as at 2 h and 6 h time 
points for both types of transfection. These results were confirmed by CLSM, where several 
complexes were observed inside the cells 2 h after transfection (data are not shown). According 
to the protocol for hMSC transfection, used in this work, changing of cell culture medium was 
always performed 4 h after transfection. That was done, aiming to discard the complexes, which 
had not been internalized by the cells, thus improving culture conditions. Hence, all the further 
measurements of reporter gene expression reflected the pDNA within the cells at 4 h time point 
post-transfection, similar to all other experiments, performed in this work. At 12 h time point 
a significant difference in luciferase activity after pDNA/PEI- and magnetic polyplexes- 
mediated transfection was observed (Fig. 3.4). Though reporter gene expression slightly 
increased at subsequent time points between 12 and 48 h, the majority of the cells was most 
probably transfected already at 12 h time point post-transfection.  
4.2 Mechanism of MNP-mediated transfection  
4.2.1 Insights the mechanism of transfection 
The monitoring of luciferase reporter gene activity overtime after transfection with 
pDNA/PEI or magnetic polyplexes showed that both carriers provide a rapid gene delivery in 
hMSC. However, transfection with pDNA/PEI/MNP complexes was more efficient, than with 
polyplexes even in the absence of a magnetic field (Fig. 3.4). In order to understand the reasons 
for this effect, the transfection mechanism will be discussed and investigated below.  
It has been previously shown that size, charge and structure of transfection complexes have 
a significant influence on their internalization route and intracellular kinetics [158-160]. The 
effective diameters of transfection complexes, used in this work, were significantly different, 
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but still less than 120 nm (see section 4.1.1 and Table 3.1). Hence, their cellular uptake and 
further processing should follow similar routes with comparable speed [160].  
The next step after cellular entry is the transportation of transfection complexes towards 
the nucleus in endosomes. This process has undergone extensive investigation on different PEI-
based polymers, used for transfection [161-164]. Due to a “proton sponge” effect of PEI, 
polyplexes can efficiently escape lysosomal degradation and easily release pDNA in the 
cytoplasm [165-167]. Many research groups, studying this process, stated that PEI is able to 
“buffer” lysosomes by increasing their pH value [168, 169]. However, this hypothesis has 
recently been challenged, as no PEI – induced changes in lysosomal pH were observed [112, 
170]. Nevertheless, it is evident, that polyplexes reach lysosomes to a high extent and still 
provide efficient gene delivery, although the exact mechanism of lysosomal escape and pDNA 
release remain unclear.  
At the last stage of the intracellular route of transfection complexes, the released pDNA 
enters the nucleus via various mechanisms, which are still extensively discussed. Under 
consideration are the entry via the nuclear pore complex, passive transfer during mitosis and 
undefined pathways, occurring in non-dividing cells [171].  
While the mechanism of polyplex-mediated transfection has been in focus since decades, 
MNP-mediated transfection processes were not studied in details. The mechanism of 
magnetofection was reported by Huth et al. in 2004 [143]. However, their studies focused on 
the cellular entry of transfection complexes and the influence of an external magnetic field on 
this process. In general, they assumed that the mechanism of MNP-mediated transfection was 
similar to that of pDNA/PEI complexes and therefore was not studied in detail. They claimed 
that magnetic field, involved in magnetofection, had no influence on cellular entry and further 
processing of transfection complexes [143]. Thus, the efficiency of magnetically-assisted 
transfection was enhanced due to more rapid sedimentation of transfection complexes on the 
cell surface [143].  
All transfection experiments in current work were performed in the absence of a magnetic 
field, clearly indicating that MNP are able to positively affect transfection efficiency of 
polyplexes without external magnetic exposure. The expected mechanism of magnetic 
polyplex-mediated transfection in comparison to polyplexes is shown in Figure 4.1 [124].  
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To better understand the mechanism of MNP-based transfection and prove the hypothesis 
in this work, transfection complexes were visualized and observed inside the cells at different 
time points after transfection. 
4.2.2 Visualization of transfection complexes 
The choice of appropriate methods is a crucial step in any research work, dedicated to study 
intracellular mechanisms, processes or pathways. It very much depends on the study objectives 
and investigated material. Different methodologies were previously successfully employed in 
order to reveal the mechanism of transfection (e.g. cellular uptake studies [158], electron 
Figure 4.1: Expected mechanism of magnetic polyplex-mediated transfection in comparison to polyplexes. After 
cellular entry via endocytosis (1) both types of transfection complexes are transported along the cytoskeleton 
towards the nucleus (2). Next, pDNA alone or the whole complexes should be released from endosomes to 
perinuclear region (3), thus avoiding their exocytosis (5A) or lysosomal degradation (5B). The final step of 
successful transfection process is the nuclear entry of pDNA (4) followed by transcription or translation. In case of 
polyplexes, cationic polymer can also enter the nucleus. In case of MNP-based transfection, cationic polymer is 
expected to remain in the cytoplasm. Retrieved and adapted from http://www.futuremedicine.com/ [124].   
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microscopy [143], confocal microscopy [158, 172], single particle tracking [173], labelling 
with quantum dots [174], Förster Resonance Energy Transfer (FRET) [175]). 
To investigate the transfection mechanism, in this study confocal microscopy was used. 
For that, transfection complexes were visualized via fluorescent labelling techniques. This 
method is wide spread due to relative simplicity, wide selection of labelling reagents, broad 
application spectrum and universality. It may allow to obtain both, qualitative and quantitative 
data about intracellular trafficking of transfection complexes.  
For the first time, in this work all three components of magnetic polyplexes (pDNA, PEI 
and MNP) were fluorescently labelled and visualized at once.  
Fluorescent labelling protocols were initially optimized in order to maintain the 
functionality and the safety of transfection agents in COS-7 cells. These data were described 
in details by Anna Schade [150]. It current work, the performance of both, single-labelled and 
three-color labelled complexes, was tested in hMSC (Fig. 3.5). Additionally, the influence of 
labelling on size and surface charge of transfection complexes was evaluated by DLS and 
PALS methods (Table 3.3). Despite the slight increase in size of magnetic polyplexes, labelled 
transfection complexes provided high transfection efficiency and high cell viability in hMSC. 
The values were not significantly different from those, obtained for unlabelled complexes (Fig. 
3.5). Thus, the labelling protocol was confirmed to be optimal also for hMSC, which allowed 
the correlation of microscopy data with in vitro transfection data in the following experiments.  
SIM is a modern high – resolution technique with maximum resolution of 50-110 nm, 
which was employed in this work for the visualization of magnetic polyplexes without the cell 
environment [176, 177]. All three fluorescent signals (representing pDNA, PEI and MNP) had 
a good signal-to-noise ratio and were visually colocalized. Magnetic polyplexes had a spherical 
shape and size ranging from 200 nm to 300 nm. Furthermore, no single or two-color signals 
were detected, that can indicate that all pDNA was condensed in pDNA/PEI complexes, and 
all pDNA/PEI complexes were bound to MNP (Fig. 3.5).  
However, close localization of the fluorophores inside the transfection complex, as well as 
their close emission/excitation spectra may trigger certain undesired interactions. An example 
of such interactions is FRET – a transfer of energy with subsequent false detection of one 
fluorophore in a wrong channel. It mostly occurs between fluorophores with close excitation 
and emission spectra, when the distance between them does not exceed 10 nm [178]. The 
presence of FRET between pairs of OG488/A565 and A565/Cy5 in labelled transfection 
complexes was studied in photobleaching experiments (Fig. 3.6). Importantly, no FRET was 
detected for magnetic polyplexes in this work, indicating that labelling procedures and 
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microscopic acquisition set up were optimal. These points were extremely important for 
reliable colocalization studies later on. 
4.2.3 Intracellular localization of transfection complexes 
Fluorescently labelled transfection complexes were observed in hMSC by means of CLSM 
at different time points after transfection. Already at 2 h time point both, pDNA/PEI and 
pDNA/PEI/MNP have entered the cell and were randomly distributed inside (data are not 
shown). However, this work was focused on the perinuclear region, as pDNA release process 
and its further nuclei entry are the most crucial steps of transfection [179]. Pollard et al. showed 
that only 1/1000 of cytosolically injected pDNA could be delivered to the cell nucleus and 
successfully expressed [180]. However, knowledge of the processes taking place in the 
perinuclear region during transfection is still insufficient.  
Therefore, we performed an optical sectioning of transfected cells, focusing on the nucleus 
and perinuclear region. This revealed that in case of pDNA/PEI-mediated transfection pDNA 
delivered into the nuclei was still condensed by PEI (Fig. 3.7a and 3.8b, b`). In 2008, our group 
had already detected similar events [144], yet in COS-7 cells. These findings are in agreement 
with other reports, published earlier [181-183]. It is generally considered that most of the 
polyplexes enter the nucleus via temporary opening of the nuclear membrane during mitosis 
[171]. This hypothesis corresponds well to the studies where transfection efficiency was shown 
to be a cell cycle dependent process [184, 185]. Nevertheless, polyplex-mediated transfection 
was also successfully performed in non-dividing cells [186], thus indicating that pDNA is able 
to enter the nucleus of those cells in either free or condensed form [171]. However, the 
mechanism of this import remains unclear.  
On the contrary, in cells which underwent magnetic polyplex-mediated transfection, pDNA 
signals inside the nuclei were colocalized neither with PEI - , nor with MNP – signals (Fig. 
3.8a``). Moreover, it was possible for the first time to observe three different events in one 
visual field: the condensed magnetic polyplexes, complexes releasing pDNA in the perinuclear 
region and pDNA inside the nucleus (Fig. 3.8a``). 
In 2008 it was already hypothesized, that pDNA/PEI and pDNA/PEI/MNP complexes 
follow different transfection mechanisms in terms of nuclear entry of pDNA [144]. The results 
described in this work, allow to confirm the hypothesis of Li et al. via demonstration of free 
intranuclear pDNA. Furthermore, morphological changes in composition of transfection 
complexes, presented in Figure 3.8a`` (2), can be explained by the process of pDNA release, 
which has not been reported previously. Importantly, in cells transfected by means of 
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pDNA/PEI complexes no similar processes were found, thus these events were exclusive for 
magnetic polyplex-mediated gene delivery. Hence, magnetic polyplexes may provide a more 
efficient pDNA release than polyplexes. In order to prove this hypothesis and provide 
quantitative data, the following pDNA release studies were performed.   
4.2.4 Monitoring of pDNA release from transfection complexes  
For monitoring of intracellular pDNA release process, colocalization of pDNA-Cy5/PEI-
OG488 and PEI-OG488/MNP-A565 signals was evaluated using CLSM at different time 
points after transfection (Fig. 3.9). At the initial time point (2 h post transfection) pDNA was 
significantly more condensed inside magnetic polyplexes, than in pDNA/PEI complexes. This 
fact might be of benefit for transfection due to better protection of pDNA from degradation in 
the cytoplasm. Overall, in 24 h the values of measured Ccoef  indicated the release of pDNA 
from both, pDNA/PEI and pDNA/PEI/MNP complexes, though this process was twice more 
efficient in the case of magnetic polyplexes (26.8% vs. 58.3%) (Fig. 3.9a). These data were 
supported by the microscopic observations (see Section 4.2.3), where pDNA release events 
could only be found in the perinuclear region of cells, transfected with pDNA/PEI/MNP 
complexes. However, due to the fast degradation of free pDNA by nucleases, the location of 
this process becomes a crucial factor for successful transfection. Another important result of 
colocalization studies was a strong colocalization of PEI with MNP within magnetic polyplexes 
at all investigated time points (Fig. 3.9b). This indicated that pDNA release was related only 
to the pDNA/PEI decondensation process. The strong MNP-PEI connection is feasible due to 
the robust streptavidin-biotin interaction, which lies in the basis of magnetic polyplex-structure 
(see Section 1.5 and Fig. 1.4). As streptavidin – biotin interaction is one of the strongest 
noncovalent bindings in nature, it might retain PEI better than physical interactions and 
therefore allow an easy and efficient process of pDNA release. Moreover, due to the size of 
streptavidin – coated MNP, they are not able to enter the nucleus, thus retaining PEI in the 
perinuclear region. Some studies previously reported that efficiency of transfection depends on 
the number of plasmids, delivered to the nuclei [179, 187]. Moreover, Glover et al. assumed 
that the transcriptional activity of delivered pDNA can be affected by the carrier. For instance, 
polyplexes dissociating from the pDNA in the nucleus [180], interact with nuclear proteins and 
interfere with transcriptional machinery, resulting to cytotoxicity and limited transfection 
efficiency [179, 182]. Therefore, a system, which can efficiently release pDNA in the 
cytoplasm and does not allow the entrance of other reagents into the nucleus, may indeed 
provide better transfection rates, which has been demonstrated in this study.  
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4.3 Transfection with LMW PEI-based magnetic complexes 
In the last decades PEI has been widely used alone or in combination with other reagents 
as an efficient transfection system both, in vitro and in vivo [111]. Due to its beneficial 
properties (see Section 1.4.2.2) PEI remains in the focus of nonviral gene delivery research. 
However, its cytotoxicity and inability to biodegrade are not favorable for in vivo applications 
and limit further clinical translation of PEI-based transfection systems. PEI, most successfully 
used for transfection experiments has a MW of 25 kDa. However, it has been demonstrated 
that PEI with lower MW (600 – 2000 Da) possesses much lower cytotoxicity, though not 
providing the desired transfection efficiency [116].  
This part of the work aimed to perform a pilot investigation of magnetic polyplexes 
containing PEI with MW of 600 Da instead of a high molecular weight (HMW) PEI (MW = 
25 kDa). It was assumed that the efficiency of LMW PEI may increase due to combination 
with MNP, while magnetic polyplexes may improve their safety profile. For that 
pDNA/PEI600/MNP transfection complexes were constructed in a similar manner as HMW 
PEI-based complexes using a streptavidin – biotin connection. At first, the size and surface 
charge of pDNA/PEI600 complexes with different NP ratios were evaluated. Notably, the NP 
ratios applicable for PEI600-based complexes were higher than those for HMW PEI due to a 
low amount of aminogroups in the first case. This was in accordance with other reports, where 
LMW PEI required high NP ratios for sufficient transfection [116, 188]. At NP ratios of 40 – 
140 polyplexes had a size distribution of 160 - 230 nm and had a stable positive charge (Fig. 
3.10), indicating the sufficient condensation of pDNA by LMW PEI. Furthermore, this range 
of NP ratios was used for gene reporter transfection experiments. Optimization of 
pDNA/PEI600-mediated transfection in COS-7 cells revealed that NP 100 provided the highest 
reporter gene expression (Fig. 3.11a). In the next step, the optimization of MNP amounts within 
the magnetic polyplexes was performed. Similar to the transfection experiments with HMW 
PEI, described above, no external magnetic field was employed. Interestingly, even a small 
amount of MNP led to an increase in transfection efficiency in comparison to pDNA/PEI600 
complexes. However, magnetic polyplexes with 10 µg of MNP, NP ratio of 100 and 3 µg/cm2 
of pDNA provided the highest transfection rates (10-fold increase compared with 
pDNA/PEI600) and were considered as optimal conditions for LMW PEI-based transfection. 
These results were confirmed by EGFP transfection experiments, showed in Fig. 3.11c. The 
cytotoxicity tests showed that both, pDNA/PEI600 and pDNA/PEI600/MNP complexes are 
relatively safe and provide more than 80% of cell viability (Fig. 3.12), that was significantly 
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higher than cell viability after transfection with HMW PEI-containing polyplexes at similar 
conditions. Nevertheless, the efficiency of PEI600-based transfection complexes, even in 
combination with MNP, still could not outperform HMW PEI-containing polyplexes.   
These pilot results underlined the need for further development of different strategies for 
improvement of MNP-based transfection. Although LMW PEI in combination with MNP was 
able to provide relatively safe transfection in the COS-7 cell line, its application in “difficult – 
to transfect” cells or further in vivo studies are limited by low efficiency. Many modification 
strategies have been already introduced and tested aiming to improve the performance of LMW 
PEI. For instance, hydrophobic modifications [189, 190], appending to polyesters [191], cross 
– linking with biodegradable linkages [188], citric acid [192] or targeting ligands[193] were 
used for creating efficient and safe LMW PEI-based gene delivery carriers in vitro and in vivo. 
However, for further clinical translation, these and other modifications should still undergo 
extensive investigations, and their targeting abilities should be improved. 
4.4 Future perspectives of MNP-based gene delivery 
Due to broad investigations on MNP-based gene delivery systems, including current work, 
this promising approach is able under certain conditions to outperform other nonviral 
transfection methods in terms of safety and efficiency. However, several drawbacks still limit 
its “bench-to-bedside” translation. Table 4.1 summarizes the most important properties and 
knowledge, which have to be considered before successful clinical translation of MNP-based 
transfection systems in the future. The table also shows the compliance of both, magnetic 
polyplexes, studied in this work and magnetofection complexes, with the listed requirements.   
 
Table 4.1: Properties of MNP-based gene delivery systems, relevant for their future clinical translation. 
 
Transfection method Comments / 
References pDNA/PEI/MNP Magnetofection 
Easy production and 
reproducibility 
+ + [128, 136, 144, 149] 
High load of genetic material + + [128, 136, 144, 149] 
Ability to load different 
genetic material 
+ + [129, 194, 195] 
Protection of genetic 
material 
+ + [128, 136, 144, 149] 
Efficient release of genetic 
material 
+ + [143, 149] 
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Transfection method Comments / 
References pDNA/PEI/MNP Magnetofection 
Ability for controlled release 
of genetic material 
- - 
Shown for similar 
structures only 
Efficient translocation of 
genetic material to the 
nucleus 
+/- +/- 
Possible with 
modified genetic 
material [196, 197] 
Targeting potential + + 
By external magnetic 
field or targeting 
ligands [144] 
High efficiency in vitro +/- +/- 
Still not comparable 
with viral vectors 
High efficiency in vivo - - 
More studies are 
required 
Reproducibility of results + + [128, 136, 144, 149] 
High safety +/- +/- 
More studies are 
required 
Non immunogenicity +/- +/- 
Extensive studies are 
required 
Biocompatibility - - 
PEI is not 
biocompatible 
Biodegradability - - 
PEI is not 
biodegradable 
Well studied intracellular 
mechanism 
+ + [143, 149, 158] 
Well studied in vivo pathway 
and biodistribution 
- - No information 
Broad preclinical studies - - Not information 
 
According to Table 4.1, both, magnetic polyplexes presented in the current study and 
commercially available magnetofection systems, already possess many features, beneficial for 
further clinical translation. In both cases MNP facilitate the transfection process and allow the 
targeting of transfection complexes by external magnetic fields in vivo. Moreover, due to the 
magnetite core, MNP possess good biocompatibility. PEI provides efficient condensation of 
nucleic acids, their protection and further release in the cytoplasm. However, PEI used for the 
construction of both transfection systems is not biodegradable and not biocompatible because 
of its toxicity. This fact reduces biocompatibility of the whole transfection system, even though 
its overall safety is rather high. The development of more appropriate in vitro and in vivo 
techniques to study biocompatibility and cytotoxicity of the transfection systems is also 
necessary, as well as extensive investigations on behavior of nanocarriers in relevant biological 
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fluids [198, 199]. Transfection efficiency of both systems is another parameter, which still 
requires improvement, as performance of the carriers depends on the cell type and still cannot 
outperform viral gene delivery. 
The strategies to improve MNP – gene delivery include modifications of the carrier 
compounds (MNP and/or PEI) and variations of genetic material. With a focus on the recent 
advances in this field, both groups will be discussed below.     
4.4.1 Modifications of the MNP-based carrier  
The most widely used strategies to improve MNP-based gene delivery techniques include 
adjustment of transfection parameters, functionalization of MNP and modifications of a 
polymeric compound.  
Thus, biocompatibility of PEI can be improved by means of the following strategies, 
recently described by Wang et al. [111]:  
 Formation of polymeric micelles by grafting with copolymers (PEG, poly(L-
lactide-co-glycolic acid) (PLGA), poly(lactic) acid (PLA), polycaprolactone, etc.); 
 Formation of synthetic polymer nanoparticles (by use of poly(methyl 
methacrylate)); 
 Formation of biodegradable polymers (e.g. by use of tetraethylenpentamine 
(TEPA));  
 Formation of biopolymer nanoparticles (by use of chitosan, cyclodextrin, 
gelatin). 
For instance, Bansal et al. synthesized novel biodegradable polymers based on linear or 
branched LMW PEI [200]. Due to the Michael reaction (treatment with an excess of methyl 
acrylate), followed by amidation with TEPA they obtained two versatile carriers: TLP 
(TEPA@linear PEI) and TBP (TEPA@branched PEI), which were able to efficiently transfect 
mammalian cell cultures with no cytotoxicity. Moreover, the obtained transfection rates were 
higher, than those after commercially available transfection reagents (Lipofectamine®, 
Superfect® and branched PEI with MW of 25 kDa) [200].  
Wu et al. have recently presented another biodegradable modification of LMW PEI by 
means of the amphiphilic polymer Pluronic. After combination with a tumor targeting - 
multifunctional peptide, the polymer demonstrated efficient and safe reporter gene delivery in 
different cell lines (HeLa, HepG2, and NIH 3T3) [201]. Similar poly(ester amines) built on the 
basis of LMW PEI and Pluronic were reported by Wang et al. [202] They also showed higher 
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transfection rates in comparison with HMW PEI in vitro and in vivo, though were not tested 
for therapeutic gene delivery.  
Although, these polymers should still undergo in vivo testing and mechanism studies, their 
combination with MNP might result in efficient, biocompatible and safe transfection systems. 
 
Due to chemical stability under physiological conditions, high magnetic moments and low 
toxicity iron oxide MNP have good biocompatibility and therefore are already widely used in 
biomedical applications [199]. By combining them with different functional molecules 
(enzymes, antibodies, etc.) the biocompatibility of MNP can be further improved. Coating with 
other materials (PEG, chitosan, lipids, proteins) can enhance their stability and allow additional 
chemical modifications [199]. Moreover, due to modifications of the physical parameters (size, 
shape, composition, and shell-core architecture), their magnetic properties can be adjusted in 
order to improve their in vivo targeting capacity [203].  
 
Nevertheless, any functional modification of the carrier elevates its complexity (e.g. 
multistep synthesis, additional purification and characterization studies) and production costs, 
while multicomponent, heterogeneous composition rises the regulatory barriers [204]. On the 
contrary, manipulations with genetic material, might improve the performance of MNP-based 
transfection systems without challenging modifications of the carrier.     
4.4.2 Modifications of genetic material 
Despite the progress in the construction of the carrier and its compounds, the process of 
translocation of genetic material into the nucleus remains one of the main barriers for successful 
gene delivery [196]. It has been demonstrated that only a small part of pDNA (1 to 10%), 
delivered into the cytoplasm reaches the nucleus and promotes gene expression [179, 187], 
which becomes a serious “bottleneck” for transfection in non-dividing cells. The nuclear import 
of delivered pDNA can be improved by including nuclear localization sequences or 
transcription factor –binding sites in the structure of a plasmid, as well as by introducing small 
molecule ligands [196].  
For example, Vernon et al. have recently used a modified plasmid for the improvement of 
MNP-based transfection (Polymag Neo, nTMag and Neuromag) in the presence of an 
oscillating magnetic field. They showed that introduction of a DNA targeting sequence leads 
to enhanced transfection rates in model primary neurons (in comparison with Lipofectamine) 
[197]. 
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Another advanced strategy for efficient nonviral gene delivery was developed on the basis 
of transposable elements, which compose 45% of the human genome [205]. Transposable 
elements-based transfection systems combine the advantages of viruses and naked DNA, 
providing efficient and sustained modification of the genome [206]. These systems usually 
include a transposon with gene expression cassette and a source of a transposase enzyme. Both 
structures can be harbored either on the same or on different plasmids, which are usually 
delivered to the cells by means of electroporation or hydrodynamic injection [206, 207]. 
PiggyBac and Sleeping Beauty are the most successful transposon systems that have already 
been widely applied for stem cell engineering, including generation of induced pluripotent stem 
cells [207-210]. Although Sleeping Beauty has already entered the clinical trials [24], much 
research is still aiming to improve the efficiency and safety of transposable elements-based 
systems. To this end, combination with MNP may improve the delivery process in vitro and 
enhance selectivity of this approach in vivo.  
To date, the majority of gene delivery studies have been using plasmid DNA. However, the 
success of transfection with this approach strongly depends on the nuclear entry of genetic 
material [179]. Moreover, DNA-based gene therapies may lead to mutational insertions in the 
host genome, increasing the risk of tumorigenesis [211]. 
Therefore, many alternative RNA-based genetic constructs are currently in the focus of 
gene therapy. They include protein coding mRNAs and noncoding RNAs (ncRNAs). Short and 
long ncRNAs are expressed in response to the environmental stimuli and stress in the course 
of development. They were shown to have a great influence on gene expression by controlling 
the transcription process, posttranscriptional targeting and epigenetic modifications [212]. For 
instance, siRNAs represent short ncRNAs (21-23 oligonucleotides), which are able to cleave 
target mRNA, leading to a reduction in the levels of target protein. They can be designed to 
silence any gene of known sequence, thus their therapeutic potential is high. Importantly, 
siRNAs are involved just in posttranscriptional processes, which reduce possible adverse gene 
alterations [213]. Several studies have recently demonstrated successful delivery of different 
siRNA to cancer cells in vitro and in vivo by means of MNP of different structure ( e.g. MNP 
including iron oxide, PEI, PEG, chitosan, silica) [214-218]. Moreover, some of those delivery 
systems were also successfully visualized and traced by MRI [215-217]. As a nonviral gene 
therapy approach siRNA has already entered clinical trials, although a number of these studies 
is less than 10. It has been applied for treatment of ocular and respiratory diseases, as well as 
for pancreas and breast cancer [24]. For instance, siRNA against vascular endothelial growth 
factor receptor-1 (Sirna-27) as intraocular injections has undergone Phase I and II clinical trials 
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in patients with age-related macular degeneration. Another siRNA for intranasal administration 
was tested for the treatment of Respiratory Syncytial Virus (RSV) infection [24]. 
Another important group of short ncRNAs includes miRNAs. These genetic constructs are 
able to control the gene expression by regulating the majority of mammalian protein - coding 
mRNAs on the posttranscriptional level [219]. Our group has recently utilized magnetic 
transfection complexes for efficient delivery of miRNA to both, expanded and freshly isolated 
hMSC aiming to improve their therapeutic potential for cardiac regeneration [194, 195, 220]. 
It was shown that magnetic transfection complexes were able to successfully deliver miRNA 
constructs to both types of hMSC. In case of expanded hMSC MNP-based carriers provided a 
prolonged functionality of delivered miRNA as compared with polyplexes. Moreover, it was 
shown in vitro that transfected cells could be manipulated by an external magnetic field, that 
might be of benefit for potential in vivo applications [220]. The group of Yin et al. has recently 
demonstrated a combined application of MNP-based miRNA delivery and hyperthermia induce 
apoptosis in cancer cells. They used magnetic zink-doped iron oxide nanoparticles (ZnFe2O4) 
to deliver a lethal-7a miRNA, that inhibits malignant growth by simultaneous targeting of 
several pathways. Glioblastoma multiforme brain cancer cells were used as a model in that 
study. The effect was further improved by magnetic hyperthermia performed after transfection. 
Though further in vivo studies are still pending, the method might become a promising 
approach for brain cancer treatment.  
The first miRNA mimic-based drug has entered clinical trials in 2015. MRX34 (produced 
by Mirna Therapeutics, TX, USA) is a double-stranded RNA mimic of the tumor suppressor 
miRNA-34, encapsulated in a liposomal nanoparticle formulation. To date, the ongoing Phase 
I study has already involved more than 100 patients and demonstrated the very first clinical 
proof of concept in treatment of renal cell carcinoma, acral melanoma and hepatocellular 
carcinoma [89, 221]. 
The knowledge on the diversity of miRNAs and their broad regulation potential is rapidly 
growing. Many preclinical studies are currently underway and further clinical trials will follow. 
In combination with efficient and safe nonviral gene delivery systems, these genetic constructs 
might be a successful approach for both, direct and indirect gene therapy.  
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5 Conclusion 
The results of this work showed that the MNP-based gene delivery system, introduced 
previously by our group, could efficiently and safely transfect hMSC, outperforming 
polyplexes alone even in the absence of a magnetic field. Furthermore, this work provided 
important insights to the mechanism of this process. This was feasible due to successful 
visualization of transfection complexes on the intracellular level and extensive studies of the 
pDNA release process, performed in the course of the project. Importantly, a method where all 
three components of the transfection system (pDNA, PEI and MNP) were selectively labelled 
and observed inside cells was introduced here for the first time. The findings of this work 
suggested that MNP-based transfection complexes provide better transfection efficiency due 
to more efficient release of pDNA in comparison to polyplexes. This underlined a strong 
influence of the carrier composition on transfection processes and its efficacy.  
This work also included pilot tests of a magnetic transfection system, where HMW PEI was 
replaced by LMW PEI, aiming to improve the biocompatibility of the system. Although the 
safety of pDNA/PEI600/MNP complexes was rather high, the efficiency was not significantly 
improved in comparison to pDNA/PEI/MNP complexes. These results emphasized the 
necessity to further develop strategies for improvement of MNP-based transfection in order to 
proceed with the clinical translation of this approach. 
In conclusion, the MNP-based gene delivery system, investigated in this work, already 
possesses certain properties, which could be beneficial for nucleic acid based modification of 
“difficult – to – transfect” cells and subsequent clinical applications. However, this carrier still 
requires an improvement of its biocompatibility properties and safety profile, which could be 
obtained by modifications of the carrier itself and/or the carried genetic material. An overview 
of the recent development of MNP-based gene delivery methods revealed great progress in this 
field. However, extensive preclinical studies, including thorough investigations of the in vivo 
pathways as well as biodistribution of transfection systems and all their components, will be 
required prior to clinical use.   
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7 Appendix 
List of abbreviations 
µg microgram (1*10-6 gram) 
µl microliter (1*10-6 liter) 
A565 Atto 565 
AAV adeno – associated virus 
ADA adenosine deaminase 
BCA bicinchoninic acid 
bp base pairs 
BSA bovine serum albumin 
CCFM cell culture freezing medium 
Ccoef colocalization coefficient 
CD cluster of differentiation 
cDNA complementary deoxyribonucleic acid 
CFTR cystic fibrosis transmembrane regulator 
CLSM confocal laser scanning microscopy 
cm2 square centimeters 
CMV cytomegalovirus 
CO2 carbon dioxide 
COS-7 african green monkey kidney fibroblast-like cell line 
CPPs cell penetrating peptides 
Da dalton 
DAPI 4´,6-diamidino-2-phenylindole 
DLS dynamic light scattering 
DMEM Dulbecco`s Modified Eagle Medium 
DMRIE 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DOL degree of labelling 
DOPE dioleolyphosphatidylethanolamine 
DOTAP N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride 
DOTMA N-[1-(2, 3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
dsRNA double-stranded ribonucleic acid 
e.g. Exempli gratia (Latin) 
EDTA ethylenediaminetetraacetic acid 
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EGFP enhanced green fluorescent protein 
EMA European Medicines Agency 
EM-CCD electron multiplying charge coupled device 
et al. et alia (Latin) 
etc. et cetera (Latin) 
FABP-4 fatty acid binding protein- 
FBS fetal bovine serum 
FDA Food and Drug Administration 
Fe3O4 Iron (II,III) oxide or magnetite 
Fig. figure 
FRET Förster resonance energy transfer 
g gram 
g standard gravity 
GNE Glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosamine 
kinase 
h hours 
HCl Hydrochloric acid 
HEK 293 human embryonic kidney 293 cell line 
HeLa human cervical cancer cell line 
HepG2 human liver cancer cell line 
HIV human immunodeficiency virus 
HLA-B7 human leukocyte antigen serotype B7 
hMSC human mesenchymal stem cells 
HUVEC human umbilical vein endothelial cells 
i.e. id est (Latin) 
IgG immunoglobulin G 
InNP inorganic nanoparticles 
kDa kilodalton 
l liter 
LMW low molecular weight 
LPL lipoprotein lipase 
M molar 
mg milligram 
MHC major histocompatibility complex 
min minutes 
miRNA micro ribonucleic acid 
ml milliliter 
mM millimolar 
MNC mononuclear cells 
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MNP magnetic nanoparticles 
MNP-A565 magnetic nanoparticles, labelled with Atto 565 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
MSCGM mesenchymal stem cell growth medium 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
mV millivolt 
MW molecular weight 
NA numerical aperture 
NaCl Sodium chloride 
ncRNA noncoding ribonucleic acid 
ng nanogram 
NIH 3T3 mouse embryonic fibroblast cell line 
nm nanometer 
NP nitrogen/phosphate ratio 
OD optical density 
OG488 oregon green 488 
PALS phase analysis light scattering 
PAMAM poly(amidoamines) 
PBS phosphate-buffered saline 
pDNA plasmid deoxyribonucleic acid 
pDNA-Cy5 plasmid deoxyribonucleic acid labelled with Cyan 5 
PEG polyethylene glycol 
pEGFP plasmid encoding enhanced green fluorescent protein 
PEI polyethylenimine 
PEI600 polyethylenimine with molecular weight of 600 dalton 
PEI-OG488 polyethylenimine labelled with oregon green 488 
PFA paraformaldehyde 
pH molar concentration of hydrogen ions  
PLA poly(lactic) acid 
PLGA poly(L-lactide-co-glycolic acid) 
PLL poly(L-lysine) 
pmol picomol 
PVDF polyvinylidene difluoride 
RLU relative light units 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute 
RT room temperature 
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SCID severe combined immunodeficiency 
SD standard deviation 
SEM standard error of the mean 
shRNA small hairpin ribonucleic acid 
siRNA small interfering ribonucleic acid 
SR-SIM superresolution – structured illumination microscopy 
TBE Tris-borate-EDTA 
TEPA tetraethylenpentamine 
Tris trisaminomethane 
U units 
UK United Kingdom 
USA United States of America 
UV-Vis ultraviolet-visible 
VEGF vascular endothelial growth factor 
vs. versus 
w/v weight to volume 
w/w weight to weight 
αMEM Minimum essential medium alpha 
  
Appendix 
 
  
 
v 
List of figures 
Figure 1.1: Overview of the methods, utilized in gene therapy clinical trials worldwide. 
Figure 1.2: Chemical structures of cationic polymers and dendrimers mostly used as 
gene delivery carriers. 
Figure 1.3: Different strategies used for the construction of MNP-based gene carriers, by 
means of molecular  linkers (a) or physical interactions (b). 
Figure 1.4: Schematic structure of pDNA/PEI/MNP transfection complex. 
Figure 2.1: The principle of biotinylation of PEI using Sulfo-NHS-LC-Biotin linker. 
Figure 2.2: Determination of iron concentration. 
Figure 2.3: Set up for fluorescent labelling of transfection complexes. 
Figure 3.1: Gel electrophoresis of pDNA/PEI transfection complexes at different NP 
ratios (from 0.25 to 3.0) in comparison to pDNA alone. 
Figure 3.2: Optimization of transfection conditions with pDNA/PEI/MNP complexes in 
comparison to pDNA/PEI complexes (MW(PEI) = 25 kDa) in hMSC. 
Figure 3.3: Characterization of hMSC. 
Figure 3.4: Monitoring of transfection efficiency in hMSC over time. 
Figure 3.5: Characterization and visualization of fluorescently labelled transfection 
complexes. 
Figure 3.6: Photobleaching experiments. 
Figure 3.7: Intracellular localization of transfection complexes in hMSC 24 h after 
transfection. 
Figure 3.8: Intracellular localization of transfection complexes in hMSC 24 h after 
transfection, including possible pDNA release events. 
Figure 3.9: Monitoring of pDNA release from transfection complexes in hMSC. 
Figure 3.10: Characterization of pDNA/PEI600 transfection complexes. 
Figure 3.11: Optimization of transfection conditions with PEI600-containing complexes 
in COS-7 cells. 
Figure 3.12: Cytotoxicity of PEI600-mediated transfection. 
Figure 4.1: Expected mechanism of magnetic polyplex-mediated transfection in 
comparison to polyplexes. 
Appendix 
 
  
 
vi 
List of tables 
 
Table 1.1: Viral vectors most recently used in gene therapy clinical trials worldwide 
(Phase I/II) and their clinical applications (years 2005-2015). 
Table 1.2: Nonviral vectors, most recently used in gene therapy clinical trials worldwide 
(Phase I/II/III) and their clinical applications (years 2005-2015). 
Table 1.3: Examples of chemical carriers for transfection, currently available on the 
market. 
Table 2.1: Cell seeding numbers for Luciferase Reporter Gene Assay, EGFP expression 
assay and laser scanning microscopy. 
Table 2.2: List of fluorochromes and laser lines (incl. main beam splitters (MBS) used 
for their excitation. 
Table 3.1: Particle size and surface charge of magnetic nanoparticles alone and 
transfection complexes (NP ratio 2.5, 1 µg/ml iron) determined by DLS and 
PALS, respectively. 
Table 3.2: Characterization of hMSC 
Table 3.3: Particle size and surface charge of single-labelled and three-color labelled 
magnetic transfection complexes (NP ratio 2.5, 1 µg/ml iron) determined by 
DLS and PALS, respectively. 
Table 4.1: Properties of MNP-based gene delivery systems, relevant for their future 
clinical translation. 
 
 
 
 
 
 
  
Appendix 
 
  
 
vii 
Acknowledgement 
First and foremost I would like to express my greatest appreciation and thanks to Prof. Dr. 
med. Gustav Steinhoff. In 2009, he gave me a great opportunity to join his team at the 
Reference and Translation Center for Cardiac Stem Cell Therapy, which had a strong impact 
on my life and career. I am truly grateful for that chance, as well as for his supervision and 
guidance throughout the course of this work, for his motivation and support that made the 
completion of this dissertation possible.  
 
I express my special appreciation to Prof. Dr. rer. nat. Robert David for critical scientific 
discussions, valuable advices and proofreading of my dissertation.  
My great appreciation and thanks go to Prof. Olga Kudritskaya for providing me the initial 
contact with Prof. Dr. med. Gustav Steinhoff and continuous support and encouragement 
through all these years.  
Special thanks go to Dr. Nan Ma and Dr. Wenzhong Li for their scientific mentoring, 
professional advices and inspiration.  
 
My special appreciation goes to my colleague and a very good friend Dr. Anna Schade, for 
her understanding, team working, support, motivation and great time within the “nanogroup”.  
I would also like to thank Dr. Dario Furlani, Dr. Nana-Maria Wagner, Dr. Kyriaki 
Chatzivasileiou, Julia Reetz-Bäder and Erik Pittermann - nice colleagues and great friends, 
who filled these years up with energy, joy and fun. 
 
I want to extend my thanks to all the members of FKGO team: Dr. Cornelia Lux, Dr. Anna 
Skorska, Dr. Ralf Gäbel, Dr. Marion Ludwig, Dr. Christian Rimmbach, Dr. Koji Hirano, Dr. 
Weiwei Wang, Dr. Yue Zhang, Peter Mark, Julia Jung, Natalia Voronina, Frauke Hausburg, 
Paula Müller, Dorothee Scharfenberg and Margit Schwarz. Many thanks to the great 
technicians, Margit Fritsche. Madeleine Bartsch and Anita Tölk, who have always been 
supportive, professional and very helpful. Thank you all for your collaboration, team spirit and 
the great time spent in the lab.  
Moreover, I would like to thank the members of Translation Management team: Dr. Gudrun 
Tiedemann, Dr. Frauke Stähler, Dr. Ulrike Ruch, Dr. Sandra Kurzawski and Dr. Jana Große. 
My special appreciation goes to project assistants, Jana Gabriel and Katrin Höfer. Thank you 
for your professionalism, support and care in all work- and life-related issues.  
Appendix 
 
  
 
viii 
I am truly thankful to my parents, Natalia Delyagina and Mikhail Delyagin, for all their 
love, support and encouragement. I am grateful for all their efforts to provide me with 
outstanding education for the sake of my future career.  
Many thanks to my husband, Artem Zharkov and my children, Diana and Roman, for their 
endless love, patience and belief. You gave me power and inspiration essential for the 
completion of this work. Thank you.  
   
Appendix 
 
  
 
ix 
Curriculum Vitae 
 
First name / Surname  Evgenya Delyagina 
 
 
 
 
 
Nationality Russian  
Date of birth August 14, 1986 
Family Married, two children 
  
Work experience 
 
Dates January 2009 – July 2014  
Organization 
 
 
Position held 
Reference and Translation Center for Cardiac Stem Cell 
Therapies, Department of Cardiac Surgery,  
University of Rostock, Rostock, Germany 
Research fellow 
  
Dates August 2008 – December 2008 
Organization 
Position held 
Quintiles Transnational, St. Petersburg, Russia 
Clinical Trials Assistant 
  
Education and 
training
  
 
Dates January 2009 – July 2014  
Degree / Educational 
institution 
Post-graduate student (PhD) Medical Science, Medical 
faculty, University of Rostock, Rostock, Germany  
Dissertation: “Magnetic nanoparticle-based gene delivery: 
mechanisms and clinical perspectives” 
Supervisor: Prof. Dr.med. Gustav Steinhoff 
  
Dates September 2003 – June 2008  
Degree / Educational 
institution 
Master of Pharmacy, Pharmaceutical faculty, 
St.Petersburg State Chemical Pharmaceutical Academy, 
St.Petersburg, Russia 
Master thesis: “Premises and facilities of drugstores” 
Supervisor: Dr. Natalia Zolotareva 
 
 
 
Appendix 
 
  
 
x 
Dates October 2006 – May 2007 
Educational institution Scientific training, Department of Molecular Genetics, 
Institute of Experimental Medicine, St. Petersburg, Russia 
Main focus: Gene delivery to mice’ embryos 
Supervisor: Prof. Dr. Vadim Vasilyev 
  
Dates June 2006 – August 2006 
Educational institution Scientific training, The Institute of Regenerative 
Medicine, Department of Cardiac Surgery, University of 
Rostock, Rostock, Germany 
Main focus: Non-viral gene delivery to mammalian cells. 
Supervisor: PD Dr. Nan Ma 
  
Dates September 2005 – May 2006  
Educational institution Medical English, Faculty of Philology, Saint-Petersburg 
State University, St. Petersburg, Russia 
  
Dates June 2003 
Educational institution Graduate, School of General Education N258 specialized in 
Chemistry and Physics, St. Petersburg, Russia 
  
Languages English - working proficiency 
German - working proficiency (B2) 
French - elementary proficiency 
Russian - mother tongue 
 
 
  
Appendix 
 
  
 
xi 
Publication List  
1. E. Delyagina, N. Ma, W. Wang, Y. Zhang, A. Kuhlo, E. Flick, H. Gatzen, G. Steinhoff, 
W. Li „Magnetically guided transfection in suspension cells with PEI 25kDa conjugated to 
magnetic nanoparticles“. Biomedizinische Technik/Biomedical Engineering 2010; 55 
(Issue s1), 37-39. (Impact Factor 1.65) 
2. E. Delyagina, N. Ma, W. Wang, Y. Zhang, A. Kuhlo, E. Flick, H. Gatzen, G. Steinhoff, 
W. Li „PEI 600 Da conjugated to magnetic nanobeads as a non-viral vector for gene 
delivery”. Biomedizinische Technik/Biomedical Engineering 2010; 55 (Issue s1), 116-117. 
(Impact Factor 1.65) 
3. E. Delyagina, N. Ma, W. Wang, Y. Zhang, A. Kuhlo, E. Flick, H. Gatzen, F. Zhang, E. 
Burkel, G. Steinhoff, W. Li „Carbon nanotube – mediated polyethylenimine for gene 
delivery“. Biomedizinische Technik/Biomedical Engineering 2010; 55 (Issue s1), 40-41. 
(Impact Factor 1.65) 
4. E. Delyagina, W. Li, A. Schade, A. Kuhlo, N. Ma, G. Steinhoff: “Low Molecular Weight 
Polyethyleimine conjugated to magnetic nanoparticles as a vector for gene delivery“. AIP 
Conference Proceedings 1311, 2010: 479-484. 
5. E. Delyagina, W. Li, N. Ma, G. Steinhoff: „Magnetic targeting strategies in gene delivery“. 
Nanomedicine (Lond) 2011 Nov; 6(9): 1593-1604. (Impact Factor 4.889) 
6. Y. Zhang, W. Li, L. Ou, W. Wang, E. Delyagina, C. Lux, H. Sorg, K. Riehemann, G. 
Steinhoff, N. Ma. „Targeted delivery of human VEGF gene via complexes of magnetic 
nanoparticle-adenoviral vectors enhanced cardiac regeneration“. PLoS One 2012; 7(7): 
e39490. (Impact Factor 3.057) 
7. P. Donndorf, D. Useini, CA. Lux, B. Vollmar, E. Delyagina, M. Laupheimer, A. Kaminski, 
G. Steinhoff. „Analysing migratory properties of human CD 133⁺ stem cells in vivo after 
intraoperative sternal bone marrow isolation“. Cell Transplantation 2013; 22(9): 1627-35. 
(Impact Factor 2.54) 
8. C. Klopsch, R. Gäbel, A. Kaminski, P. Mark, W. Wang, A. Toelk, E. Delyagina, G. 
Kleiner, L. Koch, B. Chichkov, P. Mela, S. Jockenhoevel, N. Ma, G. Steinhoff. „Spray- 
and laser-assisted biomaterial processing for fast and efficient autologous cell-plus-matrix 
tissue engineering”. Journal of Tissue Engineering and Regenerative Medicine 2015 
Dec;9(12):E177-90. (Impact Factor 4.71) 
9. E. Grambow, F. Mueller-Graf, E. Delyagina, M. Frank, A. Kuhla, B. Vollmar. “Effect of 
the hydrogen sulfide donor GYY4137 on platelet activation and microvascular thrombus 
formation in mice”. Platelets. 2014; 25(3): 166-74. (Impact Factor 1.42) 
10. A. Schade, E. Delyagina, D. Scharfenberg, A. Skorska, C. Lux, R. David, G. Steinhoff. 
“Innovative strategy for microRNA delivery in human mesenchymal stem cells via 
Magnetic Nanoparticles”. International Journal of Molecular Sciences 2013 May 23; 
14(6): 10710-26. (Impact Factor 3.257) 
11. E. Delyagina, A. Schade, D. Scharfenberg, A. Skorska, C. Lux, W. Li, G. Steinhoff. 
„Improved transfection in human mesenchymal stem cells: effective intracellular release of 
Appendix 
 
  
 
xii 
pDNA by magnetic polyplexes“. Nanomedicine (Lond) 2014 May; 9(7): 999-1017. (Impact 
Factor 4.889)  
12. A. Schade, P. Müller, E. Delyagina, N. Voronina, A. Skorska, C. Lux, G. Steinhoff, R. 
David, G. Steinhoff. „Magnetic Nanoparticle Based Nonviral MicroRNA Delivery into 
Freshly Isolated CD105(+) hMSCs”. Stem Cells International 2014; 2014:197154. (Impact 
Factor 3.687) 
13. N. Voronina, E. Delyagina, R. David, G. Steinhoff. „Inorganic nanoparticles for gene 
delivery“. Advances and Challenges in the Delivery of Nucleic Acid Therapeutics (E-book). 
2015 October. Volume 1: 108-123.   
 
Conference Presentation List  
1. E. Delyagina, N. Ma, W. Wang, A. Kuhlo, Y. Zhang, E. Flick, H. Gatzen, G. Steinhoff, 
W. Li “PEI 600 Da conjugated to magnetic nanobeads as a non-viral vector for gene 
delivery”, 8th international Conference on the Scientific and Clinical Applications of 
magnetic carriers, May 25-29, 2010, Rostock, Germany (poster presentation) 
2. E. Delyagina, N. Ma, W. Wang, Y. Zhang, A. Kuhlo, E. Flick, H. Gatzen, G. Steinhoff, 
W. Li „Magnetically guided transfection in suspension cells with PEI 25 kDa conjugated 
to magnetic nanoparticles” BMT 2010 44. DGBMT Jahrestagung, October 05-08, 2010, 
Rostock, Germany (oral presentation) 
3. E. Delyagina “Gene and drug delivery nanotechnology”. St. Petersburg State Chemical 
Pharmaceutical Academy, May 24-25, 2011, St. Petersburg, Russia (invited lecture) 
4. E. Delyagina, A. Schade, D. Scharfenberg, A. Skorska, C.A. Lux, W. Li, G. Steinhoff. 
“Nonviral transfection in human mesenchymal stem cells via magnetic nanoparticles: 
efficient DNA release in the perinuclear region”. 3rd EACTS Meeting on Cardiac and 
Pulmonary Regeneration, December 14-15, 2012, Berlin, Germany (oral presentation)  
5. A. Schade, E. Delyagina, D. Scharfenberg, G. Steinhoff. “An innovative non-viral strategy 
for efficient microRNA delivery in human mesenchymal stem cells for regenerative 
medicine”. 3rd EACTS Meeting on Cardiac and Pulmonary Regeneration, December 14-
15, 2012, Berlin, Germany (poster presentation) 
6. A. Schade, E. Delyagina, A. Skorska, C.A. Lux, R. David, G. Steinhoff. „Efficient 
modifications of human mesenchymal stem cells using novel non-viral gene carriers for 
regenerative medicine”. 8th annual conference of the German Society for Stem Cell 
Research (GSZ), September 6, 2013, Rostock, Germany (oral presentation) 
